CN112608941B - 用于构建mc4r基因突变的肥胖症猪核移植供体细胞的crispr系统及其应用 - Google Patents
用于构建mc4r基因突变的肥胖症猪核移植供体细胞的crispr系统及其应用 Download PDFInfo
- Publication number
- CN112608941B CN112608941B CN202011504254.9A CN202011504254A CN112608941B CN 112608941 B CN112608941 B CN 112608941B CN 202011504254 A CN202011504254 A CN 202011504254A CN 112608941 B CN112608941 B CN 112608941B
- Authority
- CN
- China
- Prior art keywords
- seq
- mc4r
- plasmid
- grna
- expression vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108091033409 CRISPR Proteins 0.000 title claims abstract description 68
- 101150110867 MC4R gene Proteins 0.000 title claims abstract description 21
- 238000010354 CRISPR gene editing Methods 0.000 title claims abstract description 17
- 206010064571 Gene mutation Diseases 0.000 title abstract description 5
- 238000010449 nuclear transplantation Methods 0.000 title description 2
- 239000013612 plasmid Substances 0.000 claims abstract description 114
- 239000013598 vector Substances 0.000 claims abstract description 43
- 108020005004 Guide RNA Proteins 0.000 claims abstract description 37
- 239000013604 expression vector Substances 0.000 claims abstract description 28
- 238000010362 genome editing Methods 0.000 claims abstract description 25
- 101100129533 Sus scrofa MC4R gene Proteins 0.000 claims abstract description 10
- 108020004414 DNA Proteins 0.000 claims description 54
- 210000004027 cell Anatomy 0.000 claims description 42
- 210000002950 fibroblast Anatomy 0.000 claims description 38
- 102000053602 DNA Human genes 0.000 claims description 17
- 101000978418 Homo sapiens Melanocortin receptor 4 Proteins 0.000 claims description 9
- 102100023724 Melanocortin receptor 4 Human genes 0.000 claims description 9
- 241000282887 Suidae Species 0.000 claims description 9
- 238000010276 construction Methods 0.000 claims description 7
- 108020004682 Single-Stranded DNA Proteins 0.000 claims description 5
- 238000000137 annealing Methods 0.000 claims description 3
- 238000012795 verification Methods 0.000 claims 1
- 238000012546 transfer Methods 0.000 abstract description 2
- 108090000623 proteins and genes Proteins 0.000 description 36
- 239000002773 nucleotide Substances 0.000 description 33
- 125000003729 nucleotide group Chemical group 0.000 description 33
- 238000012163 sequencing technique Methods 0.000 description 32
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 30
- 241000282898 Sus scrofa Species 0.000 description 28
- 230000035772 mutation Effects 0.000 description 22
- 241001465754 Metazoa Species 0.000 description 20
- 208000009869 Neu-Laxova syndrome Diseases 0.000 description 20
- 238000012216 screening Methods 0.000 description 19
- 102000004169 proteins and genes Human genes 0.000 description 16
- 208000008589 Obesity Diseases 0.000 description 14
- 239000012634 fragment Substances 0.000 description 14
- 235000020824 obesity Nutrition 0.000 description 14
- 238000000034 method Methods 0.000 description 11
- 241000282414 Homo sapiens Species 0.000 description 10
- 108091027544 Subgenomic mRNA Proteins 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 238000001962 electrophoresis Methods 0.000 description 9
- 238000001890 transfection Methods 0.000 description 9
- 206010010356 Congenital anomaly Diseases 0.000 description 8
- 101100118093 Drosophila melanogaster eEF1alpha2 gene Proteins 0.000 description 8
- 238000003776 cleavage reaction Methods 0.000 description 8
- 239000003623 enhancer Substances 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 229910052754 neon Inorganic materials 0.000 description 8
- GKAOGPIIYCISHV-UHFFFAOYSA-N neon atom Chemical compound [Ne] GKAOGPIIYCISHV-UHFFFAOYSA-N 0.000 description 8
- 241000282412 Homo Species 0.000 description 7
- 238000012408 PCR amplification Methods 0.000 description 7
- 108091093126 WHP Posttrascriptional Response Element Proteins 0.000 description 7
- 230000004927 fusion Effects 0.000 description 7
- 108020001507 fusion proteins Proteins 0.000 description 7
- 102000037865 fusion proteins Human genes 0.000 description 7
- 239000003550 marker Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 230000007017 scission Effects 0.000 description 7
- 125000000539 amino acid group Chemical group 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000003780 insertion Methods 0.000 description 6
- 230000037431 insertion Effects 0.000 description 6
- 238000005215 recombination Methods 0.000 description 6
- 230000006798 recombination Effects 0.000 description 6
- 241000288906 Primates Species 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 108700028369 Alleles Proteins 0.000 description 4
- 101000834253 Gallus gallus Actin, cytoplasmic 1 Proteins 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 125000003275 alpha amino acid group Chemical group 0.000 description 4
- 238000012761 co-transfection Methods 0.000 description 4
- 238000004520 electroporation Methods 0.000 description 4
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 4
- 238000001976 enzyme digestion Methods 0.000 description 4
- 238000003209 gene knockout Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 150000007523 nucleic acids Chemical group 0.000 description 4
- 230000008506 pathogenesis Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000014616 translation Effects 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 108091034057 RNA (poly(A)) Proteins 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000008055 phosphate buffer solution Substances 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 102000001796 Melanocortin 4 receptors Human genes 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 241000282890 Sus Species 0.000 description 2
- 108010021436 Type 4 Melanocortin Receptor Proteins 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 230000030648 nucleus localization Effects 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 238000010374 somatic cell nuclear transfer Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- KVWLTGNCJYDJET-LSJOCFKGSA-N Ala-Arg-His Chemical compound C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N KVWLTGNCJYDJET-LSJOCFKGSA-N 0.000 description 1
- TTXMOJWKNRJWQJ-FXQIFTODSA-N Ala-Arg-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)C)CCCN=C(N)N TTXMOJWKNRJWQJ-FXQIFTODSA-N 0.000 description 1
- JYEBJTDTPNKQJG-FXQIFTODSA-N Ala-Asn-Met Chemical compound C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCSC)C(=O)O)N JYEBJTDTPNKQJG-FXQIFTODSA-N 0.000 description 1
- AUFACLFHBAGZEN-ZLUOBGJFSA-N Ala-Ser-Cys Chemical compound N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O AUFACLFHBAGZEN-ZLUOBGJFSA-N 0.000 description 1
- BOKLLPVAQDSLHC-FXQIFTODSA-N Ala-Val-Cys Chemical compound C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)O)N BOKLLPVAQDSLHC-FXQIFTODSA-N 0.000 description 1
- RIQBRKVTFBWEDY-RHYQMDGZSA-N Arg-Lys-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O RIQBRKVTFBWEDY-RHYQMDGZSA-N 0.000 description 1
- VYZBPPBKFCHCIS-WPRPVWTQSA-N Arg-Val-Gly Chemical compound OC(=O)CNC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCN=C(N)N VYZBPPBKFCHCIS-WPRPVWTQSA-N 0.000 description 1
- XWGJDUSDTRPQRK-ZLUOBGJFSA-N Asn-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(N)=O XWGJDUSDTRPQRK-ZLUOBGJFSA-N 0.000 description 1
- KHCNTVRVAYCPQE-CIUDSAMLSA-N Asn-Lys-Asn Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O KHCNTVRVAYCPQE-CIUDSAMLSA-N 0.000 description 1
- YNQMEIJEWSHOEO-SRVKXCTJSA-N Asn-Tyr-Cys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC(=O)N)N)O YNQMEIJEWSHOEO-SRVKXCTJSA-N 0.000 description 1
- ILJQISGMGXRZQQ-IHRRRGAJSA-N Asp-Arg-Tyr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ILJQISGMGXRZQQ-IHRRRGAJSA-N 0.000 description 1
- RDRMWJBLOSRRAW-BYULHYEWSA-N Asp-Asn-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O RDRMWJBLOSRRAW-BYULHYEWSA-N 0.000 description 1
- MGSVBZIBCCKGCY-ZLUOBGJFSA-N Asp-Ser-Ser Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O MGSVBZIBCCKGCY-ZLUOBGJFSA-N 0.000 description 1
- JSHWXQIZOCVWIA-ZKWXMUAHSA-N Asp-Ser-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O JSHWXQIZOCVWIA-ZKWXMUAHSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000032841 Bulimia Diseases 0.000 description 1
- 206010006550 Bulimia nervosa Diseases 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- YNJBLTDKTMKEET-ZLUOBGJFSA-N Cys-Ser-Ser Chemical compound SC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O YNJBLTDKTMKEET-ZLUOBGJFSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- LPCKHUXOGVNZRS-YUMQZZPRSA-N Gly-His-Ser Chemical compound [H]NCC(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(O)=O LPCKHUXOGVNZRS-YUMQZZPRSA-N 0.000 description 1
- PDUHNKAFQXQNLH-ZETCQYMHSA-N Gly-Lys-Gly Chemical compound NCCCC[C@H](NC(=O)CN)C(=O)NCC(O)=O PDUHNKAFQXQNLH-ZETCQYMHSA-N 0.000 description 1
- LCRDMSSAKLTKBU-ZDLURKLDSA-N Gly-Ser-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)CN LCRDMSSAKLTKBU-ZDLURKLDSA-N 0.000 description 1
- YXTFLTJYLIAZQG-FJXKBIBVSA-N Gly-Thr-Arg Chemical compound NCC(=O)N[C@@H]([C@H](O)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N YXTFLTJYLIAZQG-FJXKBIBVSA-N 0.000 description 1
- IZVICCORZOSGPT-JSGCOSHPSA-N Gly-Val-Tyr Chemical compound [H]NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O IZVICCORZOSGPT-JSGCOSHPSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- QAMFAYSMNZBNCA-UWVGGRQHSA-N His-Gly-Met Chemical compound CSCC[C@H](NC(=O)CNC(=O)[C@@H](N)Cc1cnc[nH]1)C(O)=O QAMFAYSMNZBNCA-UWVGGRQHSA-N 0.000 description 1
- KQJBFMJFUXAYPK-AVGNSLFASA-N His-Met-Met Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)[C@H](CC1=CN=CN1)N KQJBFMJFUXAYPK-AVGNSLFASA-N 0.000 description 1
- BFOGZWSSGMLYKV-DCAQKATOSA-N His-Ser-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CN=CN1)N BFOGZWSSGMLYKV-DCAQKATOSA-N 0.000 description 1
- UWSMZKRTOZEGDD-CUJWVEQBSA-N His-Thr-Ser Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O UWSMZKRTOZEGDD-CUJWVEQBSA-N 0.000 description 1
- FONIDUOGWNWEAX-XIRDDKMYSA-N His-Trp-Asn Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(N)=O)C(O)=O FONIDUOGWNWEAX-XIRDDKMYSA-N 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- WXJKFRMKJORORD-DCAQKATOSA-N Lys-Arg-Ala Chemical compound NC(=N)NCCC[C@@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](N)CCCCN WXJKFRMKJORORD-DCAQKATOSA-N 0.000 description 1
- CFVQPNSCQMKDPB-CIUDSAMLSA-N Lys-Cys-Cys Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)O)N CFVQPNSCQMKDPB-CIUDSAMLSA-N 0.000 description 1
- ITWQLSZTLBKWJM-YUMQZZPRSA-N Lys-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](N)CCCCN ITWQLSZTLBKWJM-YUMQZZPRSA-N 0.000 description 1
- CAODKDAPYGUMLK-FXQIFTODSA-N Met-Asn-Ser Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O CAODKDAPYGUMLK-FXQIFTODSA-N 0.000 description 1
- ZBLSZPYQQRIHQU-RCWTZXSCSA-N Met-Thr-Val Chemical compound CSCC[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O ZBLSZPYQQRIHQU-RCWTZXSCSA-N 0.000 description 1
- LBSWWNKMVPAXOI-GUBZILKMSA-N Met-Val-Ser Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O LBSWWNKMVPAXOI-GUBZILKMSA-N 0.000 description 1
- PESQCPHRXOFIPX-UHFFFAOYSA-N N-L-methionyl-L-tyrosine Natural products CSCCC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 PESQCPHRXOFIPX-UHFFFAOYSA-N 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 102000002488 Nucleoplasmin Human genes 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- HBZBPFLJNDXRAY-FXQIFTODSA-N Ser-Ala-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O HBZBPFLJNDXRAY-FXQIFTODSA-N 0.000 description 1
- HEQPKICPPDOSIN-SRVKXCTJSA-N Ser-Asp-Tyr Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 HEQPKICPPDOSIN-SRVKXCTJSA-N 0.000 description 1
- GRRAECZXRONTEE-UBHSHLNASA-N Ser-Cys-Trp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O GRRAECZXRONTEE-UBHSHLNASA-N 0.000 description 1
- RJHJPZQOMKCSTP-CIUDSAMLSA-N Ser-His-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(N)=O)C(O)=O RJHJPZQOMKCSTP-CIUDSAMLSA-N 0.000 description 1
- WUXCHQZLUHBSDJ-LKXGYXEUSA-N Ser-Thr-Asp Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CC(O)=O)C(O)=O WUXCHQZLUHBSDJ-LKXGYXEUSA-N 0.000 description 1
- ZKOKTQPHFMRSJP-YJRXYDGGSA-N Ser-Thr-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ZKOKTQPHFMRSJP-YJRXYDGGSA-N 0.000 description 1
- 238000010459 TALEN Methods 0.000 description 1
- LMMDEZPNUTZJAY-GCJQMDKQSA-N Thr-Asp-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(O)=O LMMDEZPNUTZJAY-GCJQMDKQSA-N 0.000 description 1
- XSTGOZBBXFKGHA-YJRXYDGGSA-N Thr-His-His Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)N)O XSTGOZBBXFKGHA-YJRXYDGGSA-N 0.000 description 1
- UQCNIMDPYICBTR-KYNKHSRBSA-N Thr-Thr-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O UQCNIMDPYICBTR-KYNKHSRBSA-N 0.000 description 1
- LXXCHJKHJYRMIY-FQPOAREZSA-N Thr-Tyr-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C)C(O)=O LXXCHJKHJYRMIY-FQPOAREZSA-N 0.000 description 1
- BKIOKSLLAAZYTC-KKHAAJSZSA-N Thr-Val-Asn Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O BKIOKSLLAAZYTC-KKHAAJSZSA-N 0.000 description 1
- MNYNCKZAEIAONY-XGEHTFHBSA-N Thr-Val-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O MNYNCKZAEIAONY-XGEHTFHBSA-N 0.000 description 1
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 1
- OFNPHOGOJLNVLL-KCTSRDHCSA-N Trp-Ala-His Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)N OFNPHOGOJLNVLL-KCTSRDHCSA-N 0.000 description 1
- ZAGPDPNPWYPEIR-SRVKXCTJSA-N Tyr-Cys-Ser Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(O)=O ZAGPDPNPWYPEIR-SRVKXCTJSA-N 0.000 description 1
- HIINQLBHPIQYHN-JTQLQIEISA-N Tyr-Gly-Gly Chemical compound OC(=O)CNC(=O)CNC(=O)[C@@H](N)CC1=CC=C(O)C=C1 HIINQLBHPIQYHN-JTQLQIEISA-N 0.000 description 1
- YIKDYZDNRCNFQB-KKUMJFAQSA-N Tyr-His-Asn Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@@H](CC(=O)N)C(=O)O)N)O YIKDYZDNRCNFQB-KKUMJFAQSA-N 0.000 description 1
- QMNWABHLJOHGDS-IHRRRGAJSA-N Tyr-Met-Cys Chemical compound SC[C@@H](C(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 QMNWABHLJOHGDS-IHRRRGAJSA-N 0.000 description 1
- KWKJGBHDYJOVCR-SRVKXCTJSA-N Tyr-Ser-Cys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N)O KWKJGBHDYJOVCR-SRVKXCTJSA-N 0.000 description 1
- ZPFLBLFITJCBTP-QWRGUYRKSA-N Tyr-Ser-Gly Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)NCC(O)=O ZPFLBLFITJCBTP-QWRGUYRKSA-N 0.000 description 1
- FZSPNKUFROZBSG-ZKWXMUAHSA-N Val-Ala-Asp Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC(O)=O FZSPNKUFROZBSG-ZKWXMUAHSA-N 0.000 description 1
- WBUOKGBHGDPYMH-GUBZILKMSA-N Val-Cys-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)C(C)C WBUOKGBHGDPYMH-GUBZILKMSA-N 0.000 description 1
- KZKMBGXCNLPYKD-YEPSODPASA-N Val-Gly-Thr Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(O)=O KZKMBGXCNLPYKD-YEPSODPASA-N 0.000 description 1
- KSFXWENSJABBFI-ZKWXMUAHSA-N Val-Ser-Asn Chemical compound [H]N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O KSFXWENSJABBFI-ZKWXMUAHSA-N 0.000 description 1
- PQSNETRGCRUOGP-KKHAAJSZSA-N Val-Thr-Asn Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CC(N)=O PQSNETRGCRUOGP-KKHAAJSZSA-N 0.000 description 1
- ZHWZDZFWBXWPDW-GUBZILKMSA-N Val-Val-Cys Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(O)=O ZHWZDZFWBXWPDW-GUBZILKMSA-N 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 108010086434 alanyl-seryl-glycine Proteins 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000037237 body shape Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 101150038500 cas9 gene Proteins 0.000 description 1
- 238000010370 cell cloning Methods 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 230000019439 energy homeostasis Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- XBGGUPMXALFZOT-UHFFFAOYSA-N glycyl-L-tyrosine hemihydrate Natural products NCC(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 XBGGUPMXALFZOT-UHFFFAOYSA-N 0.000 description 1
- 108010028188 glycyl-histidyl-serine Proteins 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000037493 inherited obesity Diseases 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 108060005597 nucleoplasmin Proteins 0.000 description 1
- 235000021062 nutrient metabolism Nutrition 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000013310 pig model Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 101150013400 rag1 gene Proteins 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108010048818 seryl-histidine Proteins 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 108010017949 tyrosyl-glycyl-glycine Proteins 0.000 description 1
- 108010073969 valyllysine Proteins 0.000 description 1
- 108010027345 wheylin-1 peptide Proteins 0.000 description 1
- 108010000998 wheylin-2 peptide Proteins 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0656—Adult fibroblasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/108—Swine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2517/00—Cells related to new breeds of animals
- C12N2517/02—Cells from transgenic animals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/36—Vector systems having a special element relevant for transcription being a transcription termination element
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Environmental Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
本发明公开了用于构建MC4R基因突变的肥胖症猪核移植供体细胞的CRISPR系统及其应用。该系统包含Cas9表达载体和针对猪MC4R基因的gRNA表达载体;所述的Cas9表达载体为质粒全序列如SEQ ID NO.2所示,所述的gRNA表达载体表达SEQ ID NO.22所示的gRNA;且该表达载体的载体骨架为pKG‑U6gRNA,质粒全序列如SEQ ID NO.3所示。采用本发明筛选的gRNA联合改造的Cas9高效表达载体进行基因编辑,编辑效率比原载体有了显著的提高。
Description
技术领域
本发明属于生物技术领域,具体涉及用于MC4R基因编辑的CRISPR/Cas9系统及其应用。
背景技术
肥胖症(Obesity)是指体脂肪累积过多而对健康造成负面影响的身体状态,可能导致寿命减短及各种健康问题。尽管肥胖通常受到遗传和环境的共同影响,但肥胖症实际上是可遗传且由多基因作用的,只是不同人的易感性存在差异。在极少数情况下,遗传性肥胖症是由致病突变直接干扰能量稳态或脂肪沉积,例如人类单基因肥胖病的发生。其中,黑皮质素4受体(MC4R)基因的突变是造成人类先天性肥胖症最重要的基因之一。MC4R表达的增加可抑制食物的摄入,突变造成MC4R功能的丧失可引起肥胖、食欲亢进和严重的高胰岛素血症。因此,迫切需要开发出基于MC4R突变导致的先天性肥胖症动物模型以尽快解开发病机制谜团并为进一步的治疗奠定基础。猪作为大动物,是人类长期以来主要的肉食供应动物,易于大规模繁殖饲养,而且在伦理道德及动物保护等方面的要求较低,且猪体型大小和生理功能与人类近似,是理想的人类疾病模型动物。
基因编辑是近年来不断取得重大发展的一种生物技术,其包括从基于同源重组的基因编辑到基于核酸酶的ZFN、TALEN、CRISPR/Cas9等,其中CRISPR/Cas9技术是当前最先进的基因编辑技术。目前,基因编辑技术被越来越多地应用到动物模型的制作上。猪作为大动物,是人类长期以来主要的肉食供应动物,其体型大小和生理功能与人类近似,易于大规模繁殖饲养,而且在伦理道德及动物保护等方面要求较低,是理想的人类疾病模型动物。
发明内容
本发明的目的是针对现有技术的上述不足,提供一种用于MC4R基因编辑的CRISPR/Cas9系统。
本发明的另一目的是提供用于MC4R基因编辑的gRNA及其表达载体。
本发明的又一目的是提供所述的CRISPR/Cas9系统在构建MC4R基因突变的猪重组细胞中的应用。
本发明的目的可通过以下技术方案实现:
一种用于猪MC4R基因编辑的CRISPR/Cas9系统,包含Cas9表达载体和针对猪MC4R基因的gRNA表达载体;所述的Cas9表达载体为质粒全序列如SEQ ID NO.2所示的pU6gRNA-eEF1a-mNLS-hSpCas9-EGFP-PURO载体。
为了增加Cas9质粒的基因编辑能力,我们在购自addgene(Plasmid#42230,fromZhang Feng lab)pX330-U6-Chimeric_BB-CBh-hSpCas9(简称PX330)载体的基础上进行改造得到pU6gRNA-eEF1a-mNLS-hSpCas9-EGFP-PURO(简称粒pKG-GE3)。PX330的图谱如图1,改造方式如下:
1)去除原载体gRNA骨架中多余无效的序列;
2)改造启动子:将原有启动子(chickenβ-actin启动子)改造为具更高表达活性的EF1a启动子,增加Cas9基因的蛋白表达能力;
3)增加核定位信号:在Cas9的N端及C端均增加核定位信号编码序列(NLS),增加Cas9的核定位能力;
4)增加双筛选标记:原载体无任何筛选标记,不利于阳性转化细胞的筛选和富集,在Cas9的C端,插入P2A-EGFP-T2A-PURO,赋予载体荧光和抗性筛选能力;
5)插入WPRE和3’LTR等调控基因表达的序列:在基因读码框最后插入WPRE、3’LTR等序列,可增强Cas9基因的蛋白翻译能力。
改造后载体pU6gRNA-eEF1a-mNLS-hSpCas9-EGFP-PURO(简称pKG-GE3)及改造位点如图2,质粒全序列如SEQ ID NO:2所示;pKG-GE3的主要元件有:
1)gRNA表达元件:U6 gRNA scaffold;
2)启动子:EF1a启动子和CMV增强子;
3)含多个NLS的Cas9基因:含N端和C端多核定位信号(NLS)的Cas9基因;
4)筛选标记基因:荧光和抗性双筛选标记元件P2A-EGFP-T2A-PURO;
5)增强翻译的元件:WPRE和3’LTR增强Cas9及筛选标记基因的翻译效率;
6)转录终止信号:bGH polyA signal;
7)载体骨架:包括Amp抗性元件和ori复制子等。
质粒pKG-GE3中,具有特异融合基因;所述特异融合基因编码特异融合蛋白;
所述特异融合蛋白自N端至C端依次包括如下元件:两个核定位信号(NLS)、Cas9蛋白、两个核定位信号、自剪切多肽P2A、荧光报告蛋白、自裂解多肽T2A、抗性筛选标记蛋白;
质粒pKG-GE3中,由EF1a启动子启动所述特异融合基因的表达;
质粒pKG-GE3中,所述特异融合基因下游具有WPRE序列元件、3’LTR序列元件和bGHpoly(A)signal序列元件。
质粒pKG-GE3中,依次具有如下元件:CMV增强子、EF1a启动子、所述特异融合基因、WPRE序列元件、3’LTR序列元件、bGH poly(A)signal序列元件。
所述特异融合蛋白中,Cas9蛋白上游的两个核定位信号为SV40核定位信号,Cas9蛋白下游的两个核定位信号为nucleoplasmin核定位信号。
所述特异融合蛋白中,荧光报告蛋白具体可为EGFP蛋白。
所述特异融合蛋白中,抗性筛选标记蛋白具体可为Puromycin蛋白。
自剪切多肽P2A的氨基酸序列为“ATNFSLLKQAGDVEENPGP”(发生自剪切的断裂位置为C端开始第一个氨基酸残基和第二个氨基酸残基之间)。
自裂解多肽T2A的氨基酸序列为“EGRGSLLTCGDVEENPGP”(发生自裂解的断裂位置为C端开始第一个氨基酸残基和第二个氨基酸残基之间)。
特异融合基因具体如SEQ ID NO:2中第911-6706位核苷酸所示。
CMV增强子如SEQ ID NO:2中第395-680位核苷酸所示。
EF1a启动子如SEQ ID NO:2中第682-890位核苷酸所示。
WPRE序列元件如SEQ ID NO:2第6722-7310位核苷酸所示。
3’LTR序列元件如SEQ ID NO:2中第7382-7615位核苷酸所示。
bGH poly(A)signal序列元件如SEQ ID NO:2中第7647-7871位核苷酸所示。
作为本发明的一种优选,针对猪MC4R基因的gRNA表达载体的载体骨架为pKG-U6gRNA,质粒全序列如SEQ ID NO.3所示。
作为本发明进一步优选,该表达载体表达SEQ ID NO.22所示的gRNA,其靶点如SEQIDNO.18所示。
作为本发明更进一步优选,所述的针对猪MC4R基因的gRNA表达载体由SEQ IDNO.26和SEQ ID NO.27所示的单链DNA退火而成的双链插入载体骨架pKG-U6gRNA所得。
作为本发明的进一步优选,所述的gRNA表达载体和Cas9表达载体的摩尔比为1~3:1,进一步优选3:1。
一种重组细胞,由本发明所述的用于猪MC4R基因编辑的CRISPR/Cas9系统共转染猪原代成纤维细胞经验证后所得。
本发明所述的重组细胞在构建MC4R基因敲除的克隆猪中的应用;优选在构建MC4R基因敲除的先天性肥胖症克隆猪中的应用。
针对猪MC4R基因的gRNA,序列如SEQ ID NO.22所示。
一种针对猪MC4R基因的gRNA表达载体,该表达载体表达SEQ ID NO.22所示的gRNA;且该表达载体的载体骨架为pKG-U6gRNA,质粒全序列如SEQ ID NO.3所示;所述的gRNA表达载体优选由SEQ ID NO.26和SEQ ID NO.27所示的单链DNA退火而成的双链插入载体骨架pKG-U6gRNA的限制性内切酶BbsI位点所得。
本发明所述的CRISPR/Cas9系统、所述的gRNA表达载体在构建猪MC4R基因突变的猪重组细胞中的应用。
与现有技术相比,本发明至少具有如下有益效果:
(1)本发明研究对象(猪)比其他动物(大小鼠、灵长类)具有更好的应用性。
大小鼠等啮齿类动物不论从体型、器官大小、生理、病理等方面都与人相差巨大,无法真实地模拟人类正常的生理、病理状态。研究表明,95%以上在大小鼠中验证有效的药物在人类临床试验中是无效的。就大动物而言,灵长类是与人亲缘关系最近的动物,但其体型小、性成熟晚(6-7岁开始交配),且为单胎动物,群体扩繁速度极慢,饲养成本也高。另外,灵长类动物克隆效率低、难度大、成本高。
而猪作为模型动物就没有上述缺点,猪是除灵长类外与人亲缘关系最近的动物,其体型、体重、器官大小等与人相近,在解剖学、生理学、营养代谢、疾病发病机制方面等方面与人类极为相似。同时,猪的性成熟早(4-6个月),繁殖力高,一胎多仔,在2-3年内即可形成一个较大群体。另外,猪的克隆技术非常成熟,克隆及饲养成本较灵长类低得多;而且猪作为人类长期以来的肉食性动物,用猪作为疾病模型动物在动物保护和伦理等方面的要求较低。
(2)本发明针对猪MC4R基因设计了四个gRNA,从中筛选高效gRNA后再进行预设靶点的敲除,可有效降低后期鉴定筛选的工作量,并可直接用PCR产物测序来检测基因编辑效率。
(3)采用本发明改造的Cas9高效表达载体进行基因编辑,编辑效率比原载体提高100%以上。
(4)采用本发明改造的Cas9高效表达载体进行基因编辑,通过靶标基因PCR产物测序结果可分析出所获细胞的基因型[纯合突变(包括双等位基因相同变异的突变和双等位基因不同变异的突变)、杂合突变或野生型],获得纯合突变的概率为30%~50%,大大优于使用胚胎注射技术的模型制备方法(即受精卵注射基因编辑材料)中获得纯合突变的概率(低于5%)。
(5)利用本发明所得到的纯合突变单细胞克隆株进行体细胞核移植动物克隆可直接得到含靶标基因纯合突变的克隆猪,并且该纯合突变可稳定遗传。
在小鼠模型制作中采用的受精卵显微注射基因编辑材料后再进行胚胎移植的方法,因其直接获得纯合突变后代的概率非常低(低于5%),需要进行后代的杂交选育,这不太适用于妊娠期较长的大动物(如猪)模型制作。因此,本发明采用技术难度大、挑战性高的原代细胞体外编辑并筛选阳性编辑单细胞克隆的方法,后期再通过体细胞核移植动物克隆技术直接获得相应疾病模型猪,可大大缩短模型猪制作周期并节省人力、物力、财力。
本发明为通过基因编辑手段获得先天性肥胖症猪模型奠定了坚实的基础,将有助于研究并揭示由MC4R突变引起的先天性肥胖症发病机制,进一步的可用于进行药物筛选、药效检测、疾病病理、基因治疗及细胞治疗等研究,能够为进一步的临床应用提供有效的实验数据,进而为成功治疗人类因MC4R突变导致的先天性肥胖症提供有力的实验手段。本发明对于先天性肥胖症药物的研发及揭示该病的发病机制具有重大应用价值。
附图说明
图1为质粒pX330的结构示意图。
图2为质粒pU6gRNACas9的结构示意图。
图3为pU6gRNA-eEF1a Cas9载体的结构图谱。
图4为pU6gRNA-eEF1a Cas9+nNLS载体图谱。
图5为质粒pKG-GE3的结构示意图。
图6为质粒pKG-U6gRNA的结构示意图。
图7为将20bp左右的DNA分子(用于转录形成gRNA的靶序列结合区)插入质粒pKG-U6gRNA的示意图。
图8为质粒配比优化时的测序结果。
图9为质粒pX330和质粒pKG-GE3的效果比较时的测序结果。
图10为实施例3中以18只猪的基因组DNA为模板进行PCR扩增后的电泳图。
图11为实施例3的步骤四中的测序峰图。
图12为实施例4中得到的单细胞克隆的靶基因PCR产物电泳图。
图13为编号MC4R-6的单细胞克隆的正向测序与野生型比对的结果。
图14为编号为MC4R-20的单细胞克隆的正向测序与野生型比对的结果。
图15为编号为MC4R-15的单细胞克隆的正向测序与野生型比对的结果。
图16为编号为MC4R-4的单细胞克隆的正向测序与野生型比对的结果。
具体实施方式
下面结合具体实施方式对本发明进行进一步的详细描述,给出的实施例仅为了阐明本发明,而不是为了限制本发明的范围。以下提供的实施例可作为本技术领域普通技术人员进行进一步改进的指南,并不以任何方式构成对本发明的限制。
下述实施例中的实验方法,如无特殊说明,均为常规方法,按照本领域内的文献所描述的技术或条件或者按照产品说明书进行。下述实施例中所用的材料、试剂等,如无特殊说明,均可从商业途径得到。实施例中构建的重组质粒,均已进行测序验证。完全培养液(%为体积比):15%胎牛血清(Gibco)+83%DMEM培养基(Gibco)+1%Penicillin-Streptomycin(Gibco)+1%HEPES(Solarbio)。细胞培养条件:37℃,5%CO2、5%O2的恒温培养箱。
制备猪原代成纤维细胞的方法:①取猪耳组织0.5g,除毛,然后用75﹪酒精浸泡30-40s,然后用含5%(体积比)Penicillin-Streptomycin(Gibco)的PBS缓冲液洗涤5次,然后用PBS缓冲液洗涤一次;②用剪刀将组织剪碎,采用5mL 1%胶原酶溶液(Sigma),37℃消化1h,然后500g离心5min,弃上清;③将沉淀用1mL完全培养液重悬,然后铺入含10mL完全培养基并已用0.2%明胶(VWR)封盘的直径为10的细胞培养皿中,培养至细胞长满皿底60%左右;④完成步骤③后,采用胰蛋白酶消化并收集细胞,然后重悬于完全培养液。
实施例1、质粒的构建
1.1构建质粒pU6gRNA eEF1a-mNLS-hSpCas9-EGFP-PURO(简称质粒pKG-GE3)
原始质粒pX330-U6-Chimeric_BB-CBh-hSpCas9(简称质粒pX330),序列如SEQ IDNO:1所示。质粒pX330的结构示意图见图1。SEQ ID NO:1中,第440-725位核苷酸组成CMV增强子,第727-1208位核苷酸组成chickenβ-actin启动子,第1304-1324位核苷酸编码SV40核定位信号(NLS),第1325-5449位核苷酸编码Cas9蛋白,第5450-5497位核苷酸编码nucleoplasmin核定位信号(NLS)。
质粒pU6gRNA eEF1a-mNLS-hSpCas9-EGFP-PURO(图5),简称质粒pKG-GE3,核苷酸如SEQ IDNO:2所示。与质粒pX330相比,质粒pKG-GE3主要进行了如下改造:①去除残留的gRNA骨架序列(GTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGGCTAGTCCGTTTT),降低干扰;②将原有chickenβ-actin启动子改造为具更高表达活性的EF1a启动子,增加Cas9基因的蛋白表达能力;③在Cas9基因的上游和下游均增加核定位信号编码基因(NLS),增加Cas9蛋白的核定位能力;④原质粒无任何真核细胞筛选标记,不利于阳性转化细胞的筛选和富集,依次在Cas9基因的下游插入P2A-EGFP-T2A-PURO编码基因,赋予载体荧光和真核细胞抗性筛选能力;⑤插入WPRE元件和3’LTR序列元件,增强Cas9基因的蛋白翻译能力。
pKG-GE3质粒构建方法如下:
(1)去除gRNA骨架中多余无效的序列
质粒pX330用BbsI、XbaI酶切,回收载体片段(约8313bp左右),利用多片段重组法合成插入片段175bp(SEQ ID NO:4),与回收后载体片段重组得到pU6gRNACas9载体(图2)。
(2)改造启动子及增强子
对构建好的pU6gRNACas9载体,用XbaI和AgeI内切酶去除启动子(chickenβ-actin启动子)及增强子序列(CMV增强子),回收线性载体序列约7650bp,并利用多片段重组法合成554bp的包含CMV增强子及EF1a启动子的序列(SEQ ID NO:5),与酶切后载体pU6gRNACas9重组得到pU6gRNA-eEF1a Cas9载体(图3)。
(3)Cas9基因N端增加NLS序列
将构建好的载体pU6gRNA-eEF1a Cas9使用AgeI、BglII酶切,回收7786bp载体序列,并将增加了NLS的序列补充到酶切位点,即利用多片段重组法合成447bp的包括2个核定位信号及部分切除的Cas9编码序列(SEQ ID NO:6),重组得到pU6gRNA-eEF1a Cas9+nNLS载体(图4)。
(4)Cas9基因C端加入NLS、P2A-EGFP-T2A-PURO、WPRE-3’LTR-bGH polyA signals
以上构建好的载体命名为pU6gRNA-eEF1a Cas9+nNLS,使用FseI、SbfI酶切,回收载体序列7781bp,利用多片段重组法合成2727bp的包括NLS-P2A-EGFP-T2A-PURO-WPRE-3’LTR-bGH polyA signals的片段(SEQ ID NO:7),与载体片段重组得到载体pU6gRNA-eEF1a-mNLS-hSpCas9-EGFP-PURO,简称pKG-GE3,质粒图谱如图5,核苷酸序列(SEQ ID NO:2)。
SEQ ID NO:2中,第395-680位核苷酸组成CMV增强子,第682-890位核苷酸组成EF1a启动子,第986-1006位核苷酸编码核定位信号(NLS),第1016-1036位核苷酸编码核定位信号(NLS),第1037-5161位核苷酸编码Cas9蛋白,第5162-5209位核苷酸编码核定位信号(NLS),第5219-5266位核苷酸编码核定位信号(NLS),第5276-5332位核苷酸编码自剪切多肽P2A(自剪切多肽P2A的氨基酸序列为“ATNFSLLKQAGDVEENPGP”,发生自剪切的断裂位置为C端开始第一个氨基酸残基和第二个氨基酸残基之间),第5333-6046位核苷酸编码EGFP蛋白,第6056-6109位核苷酸编码自裂解多肽T2A(自裂解多肽T2A的氨基酸序列为“EGRGSLLTCGDVEENPGP”,发生自裂解的断裂位置为C端开始第一个氨基酸残基和第二个氨基酸残基之间),第6110-6703位核苷酸编码Puromycin蛋白(简称Puro蛋白),第6722-7310位核苷酸组成WPRE序列元件,第7382-7615位核苷酸组成3’LTR序列元件,第7647-7871位核苷酸组成bGH poly(A)signal序列元件。SEQ ID NO:2中,第911-6706形成融合基因,表达融合蛋白。由于自剪切多肽P2A和自裂解多肽T2A的存在,融合蛋白自发形成如下三个蛋白:具有Cas9蛋白的蛋白、具有EGFP蛋白的蛋白和具有Puro蛋白的蛋白。
1.2构建pKG-U6gRNA载体
来源pUC57载体,通过EcoRV酶切位点,连接pKG-U6gRNA插入序列(含U6启动子、BbsI酶切位点和sgRNA骨架序列的DNA片段,序列如SEQ ID NO:8所示),反向插入到pUC57载体,得到pKG-U6gRNA载体全序列(SEQ ID NO:3),SEQ ID NO:3中,第2280-2539位核苷酸组成hU6启动子,第2558-2637位核苷酸用于转录形成gRNA骨架。使用时,将20bp左右的DNA分子(用于转录形成gRNA的靶序列结合区)(图7)插入质粒pKG-U6gRNA(图6),形成重组质粒,在细胞中重组质粒转录得到gRNA。
实施例2、质粒pX330和质粒pKG-GE3的效果比较
选择位于RAG1基因的高效gRNA靶点:
RAG1-gRNA4的靶点:5’-AGTTATGGCAGAACTCAGTG-3’(SEQ ID NO:9)。
用于扩增和检测包含靶点的片段的引物如下:
RAG1-nF126:5’-CCCCATCCAAAGTTTTTAAAGGA-3’(SEQ ID NO:10);
RAG1-nR525:5’-TGTGGCAGATGTCACAGTTTAGG-3’(SEQ ID NO:11)
从初生从江香猪(雌性,血型AO)的耳组织制备猪原代成纤维细胞。
一、制备重组质粒
取质粒pKG-U6gRNA,用限制性内切酶BbsI进行酶切,回收载体骨架(约3kb的线性大片段)。分别合成RAG1-4S和RAG1-4A,然后混合并进行退火,得到具有粘性末端的双链DNA分子。将具有粘性末端的双链DNA分子和载体骨架连接,得到质粒pKG-U6gRNA(RAG1-gRNA4)。
RAG1-4S:5’-caccgAGTTATGGCAGAACTCAGTG-3’(SEQ ID NO:12);
RAG1-4A:5’-aaacCACTGAGTTCTGCCATAACTc-3’(SEQ ID NO:13)。
RAG1-4S和RAG1-4A均为单链DNA分子。
二、质粒配比优化
第一组:将质粒pKG-U6gRNA(RAG1-gRNA4)和质粒pKG-GE3共转染猪原代成纤维细胞。配比:约20万个猪原代成纤维细胞:0.44μg质粒pKG-U6gRNA(RAG1-gRNA4):1.56μg质粒pKG-GE3。即质粒pKG-U6gRNA(RAG1-gRNA4)和质粒pKG-GE3的摩尔配比为:1:1。
第二组:将质粒pKG-U6gRNA(RAG1-gRNA4)和质粒pKG-GE3共转染猪原代成纤维细胞。配比:约20万个猪原代成纤维细胞:0.72μg质粒pKG-U6gRNA(RAG1-gRNA4):1.28μg质粒pKG-GE3。即质粒pKG-U6gRNA(RAG1-gRNA4)和质粒pKG-GE3的摩尔配比为:2:1。
第三组:将质粒pKG-U6gRNA(RAG1-gRNA4)和质粒pKG-GE3共转染猪原代成纤维细胞。配比:约20万个猪原代成纤维细胞:0.92μg质粒pKG-U6gRNA(RAG1-gRNA4):1.08μg质粒pKG-GE3。即质粒pKG-U6gRNA(RAG1-gRNA4)和质粒pKG-GE3的摩尔配比为:3:1。
第四组:将质粒pKG-U6gRNA(RAG1-gRNA4)转染致猪原代成纤维细胞。配比:约20万个猪原代成纤维细胞:1μg质粒pKG-U6gRNA(RAG1-gRNA4)。
共转染采用电击转染的方式,采用哺乳动物核转染试剂盒(Neon kit,Thermofisher)与Neon TM transfection system电转仪(参数设置为:1450V、10ms、3pulse)。
2、完成步骤1后,采用完全培养液培养16-18小时,然后更换新的完全培养液进行培养。培养总时间为48小时。
3、完成步骤2后,采用胰蛋白酶消化并收集细胞,提取基因组DNA,采用RAG1-nF126和RAG1-nR525组成的引物对进行PCR扩增,然后进行电泳。
电泳后回收目的条带并进行测序,测序结果见图8。
通过利用Synthego ICE工具分析测序峰图得出不同靶点的编辑效率。第一组至第三组的基因编辑效率依次为9%、53%、66%。第四组不发生基因编辑。结果表明,第三组编辑效率最高,确定单gRNA质粒与Cas9质粒最适用量为摩尔比3:1,质粒实际用量为0.92μg:1.08μg。三、质粒pX330和质粒pKG-GE3的效果比较
1、共转染
RAG1-B组:将质粒pKG-U6gRNA(RAG1-gRNA4)转染猪原代成纤维细胞。配比:约20万个猪原代成纤维细胞:0.92μg质粒pKG-U6gRNA(RAG1-gRNA4)。
RAG1-330组:将质粒pKG-U6gRNA(RAG1-gRNA4)和质粒pX330共转染猪原代成纤维细胞。配比:约20万个猪原代成纤维细胞:0.92μg质粒pKG-U6gRNA(RAG1-gRNA4):1.08μg质粒pX330。
RAG1-KG组:将质粒pKG-U6gRNA(RAG1-gRNA4)和质粒pKG-GE3共转染猪原代成纤维细胞。配比:约20万个猪原代成纤维细胞:0.92μg质粒pKG-U6gRNA(RAG1-gRNA4):1.08μg质粒pKG-GE3。
共转染采用电击转染的方式,采用哺乳动物核转染试剂盒(Neon kit,Thermofisher)与Neon TM transfection system电转仪(参数设置为:1450V、10ms、3pulse)。
2、完成步骤1后,采用完全培养液培养16-18小时,然后更换新的完全培养液进行培养。培养总时间为48小时。
3、完成步骤2后,采用胰蛋白酶消化并收集细胞,提取基因组DNA,采用RAG1-nF126和RAG1-nR525组成的引物对进行PCR扩增,将产物进行测序。
通过利用Synthego ICE工具分析测序峰图得出不同靶点的编辑效率。RAG1-B组不发生基因编辑。RAG1-330组、RAG1-KG组的编辑效率依次为28%、68%。测序结果示例性峰图见图9。结果表明,与采用质粒pX330相比,采用质粒pKG-GE3使得基因编辑效率显著提高。
实施例3、用于MC4R基因敲除的靶点筛选
猪MC4R基因信息:编码melanocortin 4receptor蛋白;位于猪1号染色体;GeneID为397359,Sus scrofa。猪MC4R基因编码的蛋白质如GENBANK ACCESSION NO.NP_999338.1(linear CON 12-JAN-2018)所示。基因组DNA中,猪MC4R基因具有1个外显子,其中第1外显子如SEQ ID NO:14所示,其编码的蛋白质片段如SEQ ID NO:15所示。一、MC4R基因敲除预设靶点及邻近基因组序列保守性分析
18只初生从江香猪,其中雌性10只(分别命名1、2、3、4、5、6、7、8、9、10)、雄性8只(分别命名为A、B、C、D、E、F、G、H)。
分别以18只猪的基因组DNA为模板,采用引物对(引物对的靶序列包括猪MC4R基因第12外显子)进行PCR扩增,然后进行电泳。回收PCR扩增产物并进行测序,将测序结果与公共数据库中的MC4R基因序列进行比对分析。根据比对结果,设计用于检测突变的引物(引物本身避开可能的突变位点)。设计的用于检测突变的引物为:MC4R-E1-F/MC4R-E1-R。采用MC4R-E1-F/MC4R-E1-R组成的引物对对18只猪的基因组DNA进行PCR扩增后的电泳图见图10。
MC4R-E1-F:5’-TCCACTTCTGGAACCGCAG-3’(SEQ ID NO:16);
MC4R-E1-R:5’-TCCAACCCGCTTAACTGTCAT-3’(SEQ ID NO:17)。
二、筛选靶点
通过筛选NGG(避开可能的突变位点)初步筛选到若干靶点,经过预实验进一步从中筛选到4个靶点。
4个靶点分别如下:
sgRNAMC4R-E1-g1靶点:5’-CATCACCCTATTAAACAGCA-3’(SEQ ID NO:18);
sgRNAMC4R-E1-g2靶点:5’-CCTATTAAACAGCACGGACA-3’(SEQ ID NO:19);
sgRNAMC4R-E1-g3靶点:5’-ATGCTGGTGAGCGTTTCCAA-3’(SEQ ID NO:20);
sgRNAMC4R-E1-g4靶点:5’-CTACAGATGAAAAAGTACAT-3’(SEQ ID NO:21)。
三、制备重组质粒
取质粒pKG-U6gRNA,用限制性内切酶BbsI进行酶切,回收载体骨架(约3kb的线性大片段)。
分别合成MC4R-E1-gRNA1-S和MC4R-E1-gRNA1-A,然后混合并进行退火,得到具有粘性末端的双链DNA分子。将具有粘性末端的双链DNA分子和载体骨架连接,得到质粒pKG-U6gRNA(MC4R-E1-g1)。质粒pKG-U6gRNA(MC4R-E1-g1)表达SEQ ID NO:22所示的sgRNAMC4R-E1-g1。
分别合成MC4R-E1-gRNA2-S和MC4R-E1-gRNA2-A,然后混合并进行退火,得到具有粘性末端的双链DNA分子。将具有粘性末端的双链DNA分子和载体骨架连接,得到质粒pKG-U6gRNA(MC4R-E1-g2)。质粒pKG-U6gRNA(MC4R-E1-g2)表达SEQ ID NO:23所示的sgRNAMC4R-E1-g2。
分别合成MC4R-E1-gRNA3-S和MC4R-E1-gRNA3-A,然后混合并进行退火,得到具有粘性末端的双链DNA分子。将具有粘性末端的双链DNA分子和载体骨架连接,得到质粒pKG-U6gRNA(MC4R-E1-g3)。质粒pKG-U6gRNA(MC4R-E1-g3)表达SEQ ID NO:24所示的sgRNAMC4R-E1-g3。
分别合成MC4R-E1-gRNA4-S和MC4R-E1-gRNA4-A,然后混合并进行退火,得到具有粘性末端的双链DNA分子。将具有粘性末端的双链DNA分子和载体骨架连接,得到质粒pKG-U6gRNA(MC4R-E1-g4)。质粒pKG-U6gRNA(MC4R-E1-g4)表达SEQ ID NO:25所示的sgRNAMC4R-E1-g1。
MC4R-E1-gRNA1-S:5’-caccGCATCACCCTATTAAACAGCA-3’(SEQ ID NO:26);
MC4R-E1-gRNA1-A:5’-aaacTGCTGTTTAATAGGGTGATGC-3’(SEQ ID NO:27);
MC4R-E1-gRNA2-S:5’-caccGCCTATTAAACAGCACGGACA-3’(SEQ ID NO:28);
MC4R-E1-gRNA2-A:5’-aaacTGTCCGTGCTGTTTAATAGGC-3’(SEQ ID NO:29);
MC4R-E1-gRNA3-S:5’-caccGATGCTGGTGAGCGTTTCCAA-3’(SEQ ID NO:30);
MC4R-E1-gRNA3-A:5’-aaacTTGGAAACGCTCACCAGCATC-3’(SEQ ID NO:31);
MC4R-E1-gRNA4-S:5’-caccGCTACAGATGAAAAAGTACAT-3’(SEQ ID NO:32);
MC4R-E1-gRNA4-A:5’-aaacATGTACTTTTTCATCTGTAGC-3’(SEQ ID NO:33)。
MC4R-E1-gRNA1-S、MC4R-E1-gRNA1-A、MC4R-E1-gRNA2-S、MC4R-E1-gRNA2-A、MC4R-E1-gRNA3-S、MC4R-E1-gRNA3-A、MC4R-E1-gRNA4-S、MC4R-E1-gRNA4-A均为单链DNA分子。
四、不同靶点的编辑效率比较
从初生从江香猪(雌性,血型AO)的耳组织制备猪原代成纤维细胞。
1、共转染
第一组:将质粒pKG-U6gRNA(MC4R-E1-g1)和质粒pKG-GE3共转染猪原代成纤维细胞。配比:约20万个猪原代成纤维细胞:0.92μg质粒pKG-U6gRNA(MC4R-E1-g1):1.08μg质粒pKG-GE3。
第二组:将质粒pKG-U6gRNA(MC4R-E1-g2)和质粒pKG-GE3共转染猪原代成纤维细胞。配比:约20万个猪原代成纤维细胞:0.92μg质粒pKG-U6gRNA(MC4R-E1-g2):1.08μg质粒pKG-GE3。
第三组:将质粒pKG-U6gRNA(MC4R-E1-g3)和质粒pKG-GE3共转染猪原代成纤维细胞。配比:约20万个猪原代成纤维细胞:0.92μg质粒pKG-U6gRNA(MC4R-E1-g3):1.08μg质粒pKG-GE3。
第四组:将质粒pKG-U6gRNA(MC4R-E1-g4)和质粒pKG-GE3共转染猪原代成纤维细胞。配比:约20万个猪原代成纤维细胞:0.92μg质粒pKG-U6gRNA(MC4R-E1-g4):1.08μg质粒pKG-GE3。
第五组:猪原代成纤维细胞,未进行任何转染操作。
共转染采用电击转染的方式,采用哺乳动物核转染试剂盒(Neon kit,Thermofisher)与Neon TM transfection system电转仪(参数设置为:1450V、10ms、3pulse)。
2、完成步骤1后,采用完全培养液培养16-18小时,然后更换新的完全培养液进行培养。培养总时间为48小时。
3、完成步骤2后,采用胰蛋白酶消化并收集细胞,然后裂解细胞并提取基因组DNA,采用MC4R-E1-F和MC4R-E1-R组成的引物对进行PCR扩增,然后进行电泳。回收目标片段并进行测序,测序峰图见图11。利用Synthego ICE工具分析测序峰图得出不同靶点的基因编辑效率。第一组至第四组的基因编辑效率依次为42%、36%、2%、0%。第五组不发生基因编辑。结果表明,第一组编辑效率最高,sgRNAMC4R-E1-g1的靶点为最优靶点。
实施例4、制备MC4R基因编辑的单细胞克隆
用初生从江香猪(雌性,血型AO)的耳组织制备猪原代成纤维细胞。
1、共转染
将质粒pKG-U6gRNA(MC4R-E1-g1)和质粒pKG-GE3共转染猪原代成纤维细胞。配比:约20万个猪原代成纤维细胞:0.92μg质粒pKG-U6gRNA(MC4R-E1-g1):1.08μg质粒pKG-GE3。
共转染采用电击转染的方式,采用哺乳动物核转染试剂盒(Neon kit,Thermofisher)与Neon TM transfection system电转仪(参数设置为:1450V、10ms、3pulse)。
2、完成步骤1后,采用完全培养液培养16-18小时,然后更换新的完全培养液进行培养。培养总时间为48小时。
3、完成步骤2后,采用胰蛋白酶消化并收集细胞,用完全培养液洗涤,再用完全培养液重悬,然后分别挑取各个单细胞至96孔板的不同孔中(每个孔1个细胞,每个孔中装有100μl完全培养液),培养2周(每2-3天更换新的完全培养液)。
4、完成步骤3后,采用胰蛋白酶消化并收集细胞(每孔得到的细胞,约2/3接种到装有完全培养液的6孔板中,剩余的1/3收集在1.5mL离心管中用于后续的基因型测序检测)。
5、取步骤4的6孔板,培养至细胞长至80%汇合度,采用胰蛋白酶消化并收集细胞,使用细胞冻存液(90%完全培养基+10%DMSO,体积比)将细胞冻存。
6、取步骤4的离心管,取细胞,提取基因组DNA,采用MC4R-E1-FMC4R-E1-F和MC4R-E1-R组成的引物对进行PCR扩增,然后进行电泳。将猪原代成纤维细胞作为野生型对照。电泳图见图12。图12中的泳道编号与表1中的细胞编号一致。
7、完成步骤6后,回收PCR扩增产物并测序。
猪原代成纤维细胞的测序结果只有一种,其基因型为野生型。如果某一单细胞克隆的测序结果有两种,一种与猪原代成纤维细胞的测序结果一致,另一种与猪原代成纤维细胞的测序结果相比发生了突变(突变包括一个或多个核苷酸的缺失、插入或替换),该单细胞克隆的基因型为杂合突变型;如果某一单细胞克隆的测序结果为两种,均与猪原代成纤维细胞的测序结果相比发生了突变(突变包括一个或多个核苷酸的缺失、插入或替换),该单细胞克隆的基因型为双等位基因不同变异的纯合突变型;如果某一单细胞克隆的测序结果为一种,且与猪原代成纤维细胞的测序结果相比发生了突变(突变包括一个或多个核苷酸的缺失、插入或替换),该单细胞克隆的基因型为双等位基因相同变异的纯合突变型;如果某一单细胞克隆的测序结果为一种,且与猪原代成纤维细胞的测序结果一致,该单细胞克隆的基因型为野生型。
结果见表1。编号为4、5、54的单细胞克隆的基因型为双等位基因相同变异的纯合突变型。编号为3、8、13、15、16、18、21、25、31、37、41、44、47、51的单细胞克隆的基因型为双等位基因不同变异的纯合突变型。编号为9、10、17、20、28、34、39、43、46、53、55的单细胞克隆的基因型为杂合突变型。编号为22的单细胞克隆没有扩增出目的条带,无法判断其基因型,其余单细胞克隆均为野生型,得到基因编辑单细胞克隆的比率为28/54(即52%)。
示例性的测序比对结果见图13至图16。图13是编号为MC4R-6的单细胞克隆的正向测序与野生型比对的结果,判定为野生型。图14是编号为MC4R-20的单细胞克隆的正向测序与野生型比对的结果,判定为杂合突变型。图15是编号为MC4R-15的单细胞克隆的正向测序与野生型比对的结果,判定为双等位基因不同变异的纯合突变型。图16是编号为MC4R-4的单细胞克隆的正向测序与野生型比对的结果,判定为双等位基因相同变异的纯合突变型。
表1MC4R基因敲除的单细胞克隆基因型鉴定
以上对本发明进行了详述。对于本领域技术人员来说,在不脱离本发明的宗旨和范围,以及无需进行不必要的实验情况下,可在等同参数、浓度和条件下,在较宽范围内实施本发明。虽然本发明给出了特殊的实施例,应该理解为,可以对本发明作进一步的改进。总之,按本发明的原理,本申请欲包括任何变更、用途或对本发明的改进,包括脱离了本申请中已公开范围,而用本领域已知的常规技术进行的改变。按以下附带的权利要求的范围,可以进行一些基本特征的应用。
序列表
<110> 南京启真基因工程有限公司
<120> 用于构建MC4R基因突变的肥胖症猪核移植供体细胞的CRISPR系统及其应用
<160> 33
<170> SIPOSequenceListing 1.0
<210> 1
<211> 8484
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 1
gagggcctat ttcccatgat tccttcatat ttgcatatac gatacaaggc tgttagagag 60
ataattggaa ttaatttgac tgtaaacaca aagatattag tacaaaatac gtgacgtaga 120
aagtaataat ttcttgggta gtttgcagtt ttaaaattat gttttaaaat ggactatcat 180
atgcttaccg taacttgaaa gtatttcgat ttcttggctt tatatatctt gtggaaagga 240
cgaaacaccg ggtcttcgag aagacctgtt ttagagctag aaatagcaag ttaaaataag 300
gctagtccgt tatcaacttg aaaaagtggc accgagtcgg tgcttttttg ttttagagct 360
agaaatagca agttaaaata aggctagtcc gtttttagcg cgtgcgccaa ttctgcagac 420
aaatggctct agaggtaccc gttacataac ttacggtaaa tggcccgcct ggctgaccgc 480
ccaacgaccc ccgcccattg acgtcaatag taacgccaat agggactttc cattgacgtc 540
aatgggtgga gtatttacgg taaactgccc acttggcagt acatcaagtg tatcatatgc 600
caagtacgcc ccctattgac gtcaatgacg gtaaatggcc cgcctggcat tgtgcccagt 660
acatgacctt atgggacttt cctacttggc agtacatcta cgtattagtc atcgctatta 720
ccatggtcga ggtgagcccc acgttctgct tcactctccc catctccccc ccctccccac 780
ccccaatttt gtatttattt attttttaat tattttgtgc agcgatgggg gcgggggggg 840
ggggggggcg gggcgagggg cggggcgggg cgaggcggag aggtgcggcg gcagccaatc 900
agagcggcgc gctccgaaag tttcctttta tggcgaggcg gcggcggcgg cggccctata 960
aaaagcgaag cgcgcggcgg gcgggagtcg ctgcgcgctg ccttcgcccc gtgccccgct 1020
ccgccgccgc ctcgcgccgc ccgccccggc tctgactgac cgcgttactc ccacaggtga 1080
gcgggcggga cggcccttct cctccgggct gtaattagct gagcaagagg taagggttta 1140
agggatggtt ggttggtggg gtattaatgt ttaattacct ggagcacctg cctgaaatca 1200
ctttttttca ggttggaccg gtgccaccat ggactataag gaccacgacg gagactacaa 1260
ggatcatgat attgattaca aagacgatga cgataagatg gccccaaaga agaagcggaa 1320
ggtcggtatc cacggagtcc cagcagccga caagaagtac agcatcggcc tggacatcgg 1380
caccaactct gtgggctggg ccgtgatcac cgacgagtac aaggtgccca gcaagaaatt 1440
caaggtgctg ggcaacaccg accggcacag catcaagaag aacctgatcg gagccctgct 1500
gttcgacagc ggcgaaacag ccgaggccac ccggctgaag agaaccgcca gaagaagata 1560
caccagacgg aagaaccgga tctgctatct gcaagagatc ttcagcaacg agatggccaa 1620
ggtggacgac agcttcttcc acagactgga agagtccttc ctggtggaag aggataagaa 1680
gcacgagcgg caccccatct tcggcaacat cgtggacgag gtggcctacc acgagaagta 1740
ccccaccatc taccacctga gaaagaaact ggtggacagc accgacaagg ccgacctgcg 1800
gctgatctat ctggccctgg cccacatgat caagttccgg ggccacttcc tgatcgaggg 1860
cgacctgaac cccgacaaca gcgacgtgga caagctgttc atccagctgg tgcagaccta 1920
caaccagctg ttcgaggaaa accccatcaa cgccagcggc gtggacgcca aggccatcct 1980
gtctgccaga ctgagcaaga gcagacggct ggaaaatctg atcgcccagc tgcccggcga 2040
gaagaagaat ggcctgttcg gaaacctgat tgccctgagc ctgggcctga cccccaactt 2100
caagagcaac ttcgacctgg ccgaggatgc caaactgcag ctgagcaagg acacctacga 2160
cgacgacctg gacaacctgc tggcccagat cggcgaccag tacgccgacc tgtttctggc 2220
cgccaagaac ctgtccgacg ccatcctgct gagcgacatc ctgagagtga acaccgagat 2280
caccaaggcc cccctgagcg cctctatgat caagagatac gacgagcacc accaggacct 2340
gaccctgctg aaagctctcg tgcggcagca gctgcctgag aagtacaaag agattttctt 2400
cgaccagagc aagaacggct acgccggcta cattgacggc ggagccagcc aggaagagtt 2460
ctacaagttc atcaagccca tcctggaaaa gatggacggc accgaggaac tgctcgtgaa 2520
gctgaacaga gaggacctgc tgcggaagca gcggaccttc gacaacggca gcatccccca 2580
ccagatccac ctgggagagc tgcacgccat tctgcggcgg caggaagatt tttacccatt 2640
cctgaaggac aaccgggaaa agatcgagaa gatcctgacc ttccgcatcc cctactacgt 2700
gggccctctg gccaggggaa acagcagatt cgcctggatg accagaaaga gcgaggaaac 2760
catcaccccc tggaacttcg aggaagtggt ggacaagggc gcttccgccc agagcttcat 2820
cgagcggatg accaacttcg ataagaacct gcccaacgag aaggtgctgc ccaagcacag 2880
cctgctgtac gagtacttca ccgtgtataa cgagctgacc aaagtgaaat acgtgaccga 2940
gggaatgaga aagcccgcct tcctgagcgg cgagcagaaa aaggccatcg tggacctgct 3000
gttcaagacc aaccggaaag tgaccgtgaa gcagctgaaa gaggactact tcaagaaaat 3060
cgagtgcttc gactccgtgg aaatctccgg cgtggaagat cggttcaacg cctccctggg 3120
cacataccac gatctgctga aaattatcaa ggacaaggac ttcctggaca atgaggaaaa 3180
cgaggacatt ctggaagata tcgtgctgac cctgacactg tttgaggaca gagagatgat 3240
cgaggaacgg ctgaaaacct atgcccacct gttcgacgac aaagtgatga agcagctgaa 3300
gcggcggaga tacaccggct ggggcaggct gagccggaag ctgatcaacg gcatccggga 3360
caagcagtcc ggcaagacaa tcctggattt cctgaagtcc gacggcttcg ccaacagaaa 3420
cttcatgcag ctgatccacg acgacagcct gacctttaaa gaggacatcc agaaagccca 3480
ggtgtccggc cagggcgata gcctgcacga gcacattgcc aatctggccg gcagccccgc 3540
cattaagaag ggcatcctgc agacagtgaa ggtggtggac gagctcgtga aagtgatggg 3600
ccggcacaag cccgagaaca tcgtgatcga aatggccaga gagaaccaga ccacccagaa 3660
gggacagaag aacagccgcg agagaatgaa gcggatcgaa gagggcatca aagagctggg 3720
cagccagatc ctgaaagaac accccgtgga aaacacccag ctgcagaacg agaagctgta 3780
cctgtactac ctgcagaatg ggcgggatat gtacgtggac caggaactgg acatcaaccg 3840
gctgtccgac tacgatgtgg accatatcgt gcctcagagc tttctgaagg acgactccat 3900
cgacaacaag gtgctgacca gaagcgacaa gaaccggggc aagagcgaca acgtgccctc 3960
cgaagaggtc gtgaagaaga tgaagaacta ctggcggcag ctgctgaacg ccaagctgat 4020
tacccagaga aagttcgaca atctgaccaa ggccgagaga ggcggcctga gcgaactgga 4080
taaggccggc ttcatcaaga gacagctggt ggaaacccgg cagatcacaa agcacgtggc 4140
acagatcctg gactcccgga tgaacactaa gtacgacgag aatgacaagc tgatccggga 4200
agtgaaagtg atcaccctga agtccaagct ggtgtccgat ttccggaagg atttccagtt 4260
ttacaaagtg cgcgagatca acaactacca ccacgcccac gacgcctacc tgaacgccgt 4320
cgtgggaacc gccctgatca aaaagtaccc taagctggaa agcgagttcg tgtacggcga 4380
ctacaaggtg tacgacgtgc ggaagatgat cgccaagagc gagcaggaaa tcggcaaggc 4440
taccgccaag tacttcttct acagcaacat catgaacttt ttcaagaccg agattaccct 4500
ggccaacggc gagatccgga agcggcctct gatcgagaca aacggcgaaa ccggggagat 4560
cgtgtgggat aagggccggg attttgccac cgtgcggaaa gtgctgagca tgccccaagt 4620
gaatatcgtg aaaaagaccg aggtgcagac aggcggcttc agcaaagagt ctatcctgcc 4680
caagaggaac agcgataagc tgatcgccag aaagaaggac tgggacccta agaagtacgg 4740
cggcttcgac agccccaccg tggcctattc tgtgctggtg gtggccaaag tggaaaaggg 4800
caagtccaag aaactgaaga gtgtgaaaga gctgctgggg atcaccatca tggaaagaag 4860
cagcttcgag aagaatccca tcgactttct ggaagccaag ggctacaaag aagtgaaaaa 4920
ggacctgatc atcaagctgc ctaagtactc cctgttcgag ctggaaaacg gccggaagag 4980
aatgctggcc tctgccggcg aactgcagaa gggaaacgaa ctggccctgc cctccaaata 5040
tgtgaacttc ctgtacctgg ccagccacta tgagaagctg aagggctccc ccgaggataa 5100
tgagcagaaa cagctgtttg tggaacagca caagcactac ctggacgaga tcatcgagca 5160
gatcagcgag ttctccaaga gagtgatcct ggccgacgct aatctggaca aagtgctgtc 5220
cgcctacaac aagcaccggg ataagcccat cagagagcag gccgagaata tcatccacct 5280
gtttaccctg accaatctgg gagcccctgc cgccttcaag tactttgaca ccaccatcga 5340
ccggaagagg tacaccagca ccaaagaggt gctggacgcc accctgatcc accagagcat 5400
caccggcctg tacgagacac ggatcgacct gtctcagctg ggaggcgaca aaaggccggc 5460
ggccacgaaa aaggccggcc aggcaaaaaa gaaaaagtaa gaattcctag agctcgctga 5520
tcagcctcga ctgtgccttc tagttgccag ccatctgttg tttgcccctc ccccgtgcct 5580
tccttgaccc tggaaggtgc cactcccact gtcctttcct aataaaatga ggaaattgca 5640
tcgcattgtc tgagtaggtg tcattctatt ctggggggtg gggtggggca ggacagcaag 5700
ggggaggatt gggaagagaa tagcaggcat gctggggagc ggccgcagga acccctagtg 5760
atggagttgg ccactccctc tctgcgcgct cgctcgctca ctgaggccgg gcgaccaaag 5820
gtcgcccgac gcccgggctt tgcccgggcg gcctcagtga gcgagcgagc gcgcagctgc 5880
ctgcaggggc gcctgatgcg gtattttctc cttacgcatc tgtgcggtat ttcacaccgc 5940
atacgtcaaa gcaaccatag tacgcgccct gtagcggcgc attaagcgcg gcgggtgtgg 6000
tggttacgcg cagcgtgacc gctacacttg ccagcgcctt agcgcccgct cctttcgctt 6060
tcttcccttc ctttctcgcc acgttcgccg gctttccccg tcaagctcta aatcgggggc 6120
tccctttagg gttccgattt agtgctttac ggcacctcga ccccaaaaaa cttgatttgg 6180
gtgatggttc acgtagtggg ccatcgccct gatagacggt ttttcgccct ttgacgttgg 6240
agtccacgtt ctttaatagt ggactcttgt tccaaactgg aacaacactc aactctatct 6300
cgggctattc ttttgattta taagggattt tgccgatttc ggtctattgg ttaaaaaatg 6360
agctgattta acaaaaattt aacgcgaatt ttaacaaaat attaacgttt acaattttat 6420
ggtgcactct cagtacaatc tgctctgatg ccgcatagtt aagccagccc cgacacccgc 6480
caacacccgc tgacgcgccc tgacgggctt gtctgctccc ggcatccgct tacagacaag 6540
ctgtgaccgt ctccgggagc tgcatgtgtc agaggttttc accgtcatca ccgaaacgcg 6600
cgagacgaaa gggcctcgtg atacgcctat ttttataggt taatgtcatg ataataatgg 6660
tttcttagac gtcaggtggc acttttcggg gaaatgtgcg cggaacccct atttgtttat 6720
ttttctaaat acattcaaat atgtatccgc tcatgagaca ataaccctga taaatgcttc 6780
aataatattg aaaaaggaag agtatgagta ttcaacattt ccgtgtcgcc cttattccct 6840
tttttgcggc attttgcctt cctgtttttg ctcacccaga aacgctggtg aaagtaaaag 6900
atgctgaaga tcagttgggt gcacgagtgg gttacatcga actggatctc aacagcggta 6960
agatccttga gagttttcgc cccgaagaac gttttccaat gatgagcact tttaaagttc 7020
tgctatgtgg cgcggtatta tcccgtattg acgccgggca agagcaactc ggtcgccgca 7080
tacactattc tcagaatgac ttggttgagt actcaccagt cacagaaaag catcttacgg 7140
atggcatgac agtaagagaa ttatgcagtg ctgccataac catgagtgat aacactgcgg 7200
ccaacttact tctgacaacg atcggaggac cgaaggagct aaccgctttt ttgcacaaca 7260
tgggggatca tgtaactcgc cttgatcgtt gggaaccgga gctgaatgaa gccataccaa 7320
acgacgagcg tgacaccacg atgcctgtag caatggcaac aacgttgcgc aaactattaa 7380
ctggcgaact acttactcta gcttcccggc aacaattaat agactggatg gaggcggata 7440
aagttgcagg accacttctg cgctcggccc ttccggctgg ctggtttatt gctgataaat 7500
ctggagccgg tgagcgtgga agccgcggta tcattgcagc actggggcca gatggtaagc 7560
cctcccgtat cgtagttatc tacacgacgg ggagtcaggc aactatggat gaacgaaata 7620
gacagatcgc tgagataggt gcctcactga ttaagcattg gtaactgtca gaccaagttt 7680
actcatatat actttagatt gatttaaaac ttcattttta atttaaaagg atctaggtga 7740
agatcctttt tgataatctc atgaccaaaa tcccttaacg tgagttttcg ttccactgag 7800
cgtcagaccc cgtagaaaag atcaaaggat cttcttgaga tccttttttt ctgcgcgtaa 7860
tctgctgctt gcaaacaaaa aaaccaccgc taccagcggt ggtttgtttg ccggatcaag 7920
agctaccaac tctttttccg aaggtaactg gcttcagcag agcgcagata ccaaatactg 7980
ttcttctagt gtagccgtag ttaggccacc acttcaagaa ctctgtagca ccgcctacat 8040
acctcgctct gctaatcctg ttaccagtgg ctgctgccag tggcgataag tcgtgtctta 8100
ccgggttgga ctcaagacga tagttaccgg ataaggcgca gcggtcgggc tgaacggggg 8160
gttcgtgcac acagcccagc ttggagcgaa cgacctacac cgaactgaga tacctacagc 8220
gtgagctatg agaaagcgcc acgcttcccg aagggagaaa ggcggacagg tatccggtaa 8280
gcggcagggt cggaacagga gagcgcacga gggagcttcc agggggaaac gcctggtatc 8340
tttatagtcc tgtcgggttt cgccacctct gacttgagcg tcgatttttg tgatgctcgt 8400
caggggggcg gagcctatgg aaaaacgcca gcaacgcggc ctttttacgg ttcctggcct 8460
tttgctggcc ttttgctcac atgt 8484
<210> 2
<211> 10476
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 2
gagggcctat ttcccatgat tccttcatat ttgcatatac gatacaaggc tgttagagag 60
ataattggaa ttaatttgac tgtaaacaca aagatattag tacaaaatac gtgacgtaga 120
aagtaataat ttcttgggta gtttgcagtt ttaaaattat gttttaaaat ggactatcat 180
atgcttaccg taacttgaaa gtatttcgat ttcttggctt tatatatctt gtggaaagga 240
cgaaacaccg ggtcttcgag aagacctgtt ttagagctag aaatagcaag ttaaaataag 300
gctagtccgt tatcaacttg aaaaagtggc accgagtcgg tgcttttttc tagcgcgtgc 360
gccaattctg cagacaaatg gctctagagg tacccgttac ataacttacg gtaaatggcc 420
cgcctggctg accgcccaac gacccccgcc cattgacgtc aatagtaacg ccaataggga 480
ctttccattg acgtcaatgg gtggagtatt tacggtaaac tgcccacttg gcagtacatc 540
aagtgtatca tatgccaagt acgcccccta ttgacgtcaa tgacggtaaa tggcccgcct 600
ggcattgtgc ccagtacatg accttatggg actttcctac ttggcagtac atctacgtat 660
tagtcatcgc tattaccatg ggggcagagc gcacatcgcc cacagtcccc gagaagttgg 720
ggggaggggt cggcaattga tccggtgcct agagaaggtg gcgcggggta aactgggaaa 780
gtgatgtcgt gtactggctc cgcctttttc ccgagggtgg gggagaaccg tatataagtg 840
cagtagtcgc cgtgaacgtt ctttttcgca acgggtttgc cgccagaaca caggttggac 900
cggtgccacc atggactata aggaccacga cggagactac aaggatcatg atattgatta 960
caaagacgat gacgataaga tggcccccaa aaagaaacga aaggtgggtg ggtccccaaa 1020
gaagaagcgg aaggtcggta tccacggagt cccagcagcc gacaagaagt acagcatcgg 1080
cctggacatc ggcaccaact ctgtgggctg ggccgtgatc accgacgagt acaaggtgcc 1140
cagcaagaaa ttcaaggtgc tgggcaacac cgaccggcac agcatcaaga agaacctgat 1200
cggagccctg ctgttcgaca gcggcgaaac agccgaggcc acccggctga agagaaccgc 1260
cagaagaaga tacaccagac ggaagaaccg gatctgctat ctgcaagaga tcttcagcaa 1320
cgagatggcc aaggtggacg acagcttctt ccacagactg gaagagtcct tcctggtgga 1380
agaggataag aagcacgagc ggcaccccat cttcggcaac atcgtggacg aggtggccta 1440
ccacgagaag taccccacca tctaccacct gagaaagaaa ctggtggaca gcaccgacaa 1500
ggccgacctg cggctgatct atctggccct ggcccacatg atcaagttcc ggggccactt 1560
cctgatcgag ggcgacctga accccgacaa cagcgacgtg gacaagctgt tcatccagct 1620
ggtgcagacc tacaaccagc tgttcgagga aaaccccatc aacgccagcg gcgtggacgc 1680
caaggccatc ctgtctgcca gactgagcaa gagcagacgg ctggaaaatc tgatcgccca 1740
gctgcccggc gagaagaaga atggcctgtt cggaaacctg attgccctga gcctgggcct 1800
gacccccaac ttcaagagca acttcgacct ggccgaggat gccaaactgc agctgagcaa 1860
ggacacctac gacgacgacc tggacaacct gctggcccag atcggcgacc agtacgccga 1920
cctgtttctg gccgccaaga acctgtccga cgccatcctg ctgagcgaca tcctgagagt 1980
gaacaccgag atcaccaagg cccccctgag cgcctctatg atcaagagat acgacgagca 2040
ccaccaggac ctgaccctgc tgaaagctct cgtgcggcag cagctgcctg agaagtacaa 2100
agagattttc ttcgaccaga gcaagaacgg ctacgccggc tacattgacg gcggagccag 2160
ccaggaagag ttctacaagt tcatcaagcc catcctggaa aagatggacg gcaccgagga 2220
actgctcgtg aagctgaaca gagaggacct gctgcggaag cagcggacct tcgacaacgg 2280
cagcatcccc caccagatcc acctgggaga gctgcacgcc attctgcggc ggcaggaaga 2340
tttttaccca ttcctgaagg acaaccggga aaagatcgag aagatcctga ccttccgcat 2400
cccctactac gtgggccctc tggccagggg aaacagcaga ttcgcctgga tgaccagaaa 2460
gagcgaggaa accatcaccc cctggaactt cgaggaagtg gtggacaagg gcgcttccgc 2520
ccagagcttc atcgagcgga tgaccaactt cgataagaac ctgcccaacg agaaggtgct 2580
gcccaagcac agcctgctgt acgagtactt caccgtgtat aacgagctga ccaaagtgaa 2640
atacgtgacc gagggaatga gaaagcccgc cttcctgagc ggcgagcaga aaaaggccat 2700
cgtggacctg ctgttcaaga ccaaccggaa agtgaccgtg aagcagctga aagaggacta 2760
cttcaagaaa atcgagtgct tcgactccgt ggaaatctcc ggcgtggaag atcggttcaa 2820
cgcctccctg ggcacatacc acgatctgct gaaaattatc aaggacaagg acttcctgga 2880
caatgaggaa aacgaggaca ttctggaaga tatcgtgctg accctgacac tgtttgagga 2940
cagagagatg atcgaggaac ggctgaaaac ctatgcccac ctgttcgacg acaaagtgat 3000
gaagcagctg aagcggcgga gatacaccgg ctggggcagg ctgagccgga agctgatcaa 3060
cggcatccgg gacaagcagt ccggcaagac aatcctggat ttcctgaagt ccgacggctt 3120
cgccaacaga aacttcatgc agctgatcca cgacgacagc ctgaccttta aagaggacat 3180
ccagaaagcc caggtgtccg gccagggcga tagcctgcac gagcacattg ccaatctggc 3240
cggcagcccc gccattaaga agggcatcct gcagacagtg aaggtggtgg acgagctcgt 3300
gaaagtgatg ggccggcaca agcccgagaa catcgtgatc gaaatggcca gagagaacca 3360
gaccacccag aagggacaga agaacagccg cgagagaatg aagcggatcg aagagggcat 3420
caaagagctg ggcagccaga tcctgaaaga acaccccgtg gaaaacaccc agctgcagaa 3480
cgagaagctg tacctgtact acctgcagaa tgggcgggat atgtacgtgg accaggaact 3540
ggacatcaac cggctgtccg actacgatgt ggaccatatc gtgcctcaga gctttctgaa 3600
ggacgactcc atcgacaaca aggtgctgac cagaagcgac aagaaccggg gcaagagcga 3660
caacgtgccc tccgaagagg tcgtgaagaa gatgaagaac tactggcggc agctgctgaa 3720
cgccaagctg attacccaga gaaagttcga caatctgacc aaggccgaga gaggcggcct 3780
gagcgaactg gataaggccg gcttcatcaa gagacagctg gtggaaaccc ggcagatcac 3840
aaagcacgtg gcacagatcc tggactcccg gatgaacact aagtacgacg agaatgacaa 3900
gctgatccgg gaagtgaaag tgatcaccct gaagtccaag ctggtgtccg atttccggaa 3960
ggatttccag ttttacaaag tgcgcgagat caacaactac caccacgccc acgacgccta 4020
cctgaacgcc gtcgtgggaa ccgccctgat caaaaagtac cctaagctgg aaagcgagtt 4080
cgtgtacggc gactacaagg tgtacgacgt gcggaagatg atcgccaaga gcgagcagga 4140
aatcggcaag gctaccgcca agtacttctt ctacagcaac atcatgaact ttttcaagac 4200
cgagattacc ctggccaacg gcgagatccg gaagcggcct ctgatcgaga caaacggcga 4260
aaccggggag atcgtgtggg ataagggccg ggattttgcc accgtgcgga aagtgctgag 4320
catgccccaa gtgaatatcg tgaaaaagac cgaggtgcag acaggcggct tcagcaaaga 4380
gtctatcctg cccaagagga acagcgataa gctgatcgcc agaaagaagg actgggaccc 4440
taagaagtac ggcggcttcg acagccccac cgtggcctat tctgtgctgg tggtggccaa 4500
agtggaaaag ggcaagtcca agaaactgaa gagtgtgaaa gagctgctgg ggatcaccat 4560
catggaaaga agcagcttcg agaagaatcc catcgacttt ctggaagcca agggctacaa 4620
agaagtgaaa aaggacctga tcatcaagct gcctaagtac tccctgttcg agctggaaaa 4680
cggccggaag agaatgctgg cctctgccgg cgaactgcag aagggaaacg aactggccct 4740
gccctccaaa tatgtgaact tcctgtacct ggccagccac tatgagaagc tgaagggctc 4800
ccccgaggat aatgagcaga aacagctgtt tgtggaacag cacaagcact acctggacga 4860
gatcatcgag cagatcagcg agttctccaa gagagtgatc ctggccgacg ctaatctgga 4920
caaagtgctg tccgcctaca acaagcaccg ggataagccc atcagagagc aggccgagaa 4980
tatcatccac ctgtttaccc tgaccaatct gggagcccct gccgccttca agtactttga 5040
caccaccatc gaccggaaga ggtacaccag caccaaagag gtgctggacg ccaccctgat 5100
ccaccagagc atcaccggcc tgtacgagac acggatcgac ctgtctcagc tgggaggcga 5160
caaaaggccg gcggccacga aaaaggccgg ccaggcaaaa aagaaaaagg gcggctccaa 5220
gcggcctgcc gcgacgaaga aagcgggaca ggccaagaaa aagaaaggat ccggcgcaac 5280
aaacttctct ctgctgaaac aagccggaga tgtcgaagag aatcctggac cggtgagcaa 5340
gggcgaggag ctgttcaccg gggtggtgcc catcctggtc gagctggacg gcgacgtaaa 5400
cggccacaag ttcagcgtgt ccggcgaggg cgagggcgat gccacctacg gcaagctgac 5460
cctgaagttc atctgcacca ccggcaagct gcccgtgccc tggcccaccc tcgtgaccac 5520
cctgacctac ggcgtgcagt gcttcagccg ctaccccgac cacatgaagc agcacgactt 5580
cttcaagtcc gccatgcccg aaggctacgt ccaggagcgc accatcttct tcaaggacga 5640
cggcaactac aagacccgcg ccgaggtgaa gttcgagggc gacaccctgg tgaaccgcat 5700
cgagctgaag ggcatcgact tcaaggagga cggcaacatc ctggggcaca agctggagta 5760
caactacaac agccacaacg tctatatcat ggccgacaag cagaagaacg gcatcaaggt 5820
gaacttcaag atccgccaca acatcgagga cggcagcgtg cagctcgccg accactacca 5880
gcagaacacc cccatcggcg acggccccgt gctgctgccc gacaaccact acctgagcac 5940
ccagtccgcc ctgagcaaag accccaacga gaagcgcgat cacatggtcc tgctggagtt 6000
cgtgaccgcc gccgggatca ctctcggcat ggacgagctg tacaagggct ccggcgaggg 6060
caggggaagt cttctaacat gcggggacgt ggaggaaaat cccggcccaa ccgagtacaa 6120
gcccacggtg cgcctcgcca cccgcgacga cgtccccagg gccgtacgca ccctcgccgc 6180
cgcgttcgcc gactaccccg ccacgcgcca caccgtcgat ccggaccgcc acatcgagcg 6240
ggtcaccgag ctgcaagaac tcttcctcac gcgcgtcggg ctcgacatcg gcaaggtgtg 6300
ggtcgcggac gacggcgccg cggtggcggt ctggaccacg ccggagagcg tcgaagcggg 6360
ggcggtgttc gccgagatcg gcccgcgcat ggccgagttg agcggttccc ggctggccgc 6420
gcagcaacag atggaaggcc tcctggcgcc gcaccggccc aaggagcccg cgtggttcct 6480
ggccaccgtc ggagtctcgc ccgaccacca gggcaagggt ctgggcagcg ccgtcgtgct 6540
ccccggagtg gaggcggccg agcgcgccgg ggtgcccgcc ttcctggaga cctccgcgcc 6600
ccgcaacctc cccttctacg agcggctcgg cttcaccgtc accgccgacg tcgaggtgcc 6660
cgaaggaccg cgcacctggt gcatgacccg caagcccggt gcctgaacgc gttaagtcga 6720
caatcaacct ctggattaca aaatttgtga aagattgact ggtattctta actatgttgc 6780
tccttttacg ctatgtggat acgctgcttt aatgcctttg tatcatgcta ttgcttcccg 6840
tatggctttc attttctcct ccttgtataa atcctggttg ctgtctcttt atgaggagtt 6900
gtggcccgtt gtcaggcaac gtggcgtggt gtgcactgtg tttgctgacg caacccccac 6960
tggttggggc attgccacca cctgtcagct cctttccggg actttcgctt tccccctccc 7020
tattgccacg gcggaactca tcgccgcctg ccttgcccgc tgctggacag gggctcggct 7080
gttgggcact gacaattccg tggtgttgtc ggggaaatca tcgtcctttc cttggctgct 7140
cgcctgtgtt gccacctgga ttctgcgcgg gacgtccttc tgctacgtcc cttcggccct 7200
caatccagcg gaccttcctt cccgcggcct gctgccggct ctgcggcctc ttccgcgtct 7260
tcgccttcgc cctcagacga gtcggatctc cctttgggcc gcctccccgc gtcgacttta 7320
agaccaatga cttacaaggc agctgtagat cttagccact ttttaaaaga aaagggggga 7380
ctggaagggc taattcactc ccaacgaaga caagatctgc tttttgcttg tactgggtct 7440
ctctggttag accagatctg agcctgggag ctctctggct aactagggaa cccactgctt 7500
aagcctcaat aaagcttgcc ttgagtgctt caagtagtgt gtgcccgtct gttgtgtgac 7560
tctggtaact agagatccct cagacccttt tagtcagtgt ggaaaatctc tagcagggcc 7620
cgtttaaacc cgctgatcag cctcgactgt gccttctagt tgccagccat ctgttgtttg 7680
cccctccccc gtgccttcct tgaccctgga aggtgccact cccactgtcc tttcctaata 7740
aaatgaggaa attgcatcgc attgtctgag taggtgtcat tctattctgg ggggtggggt 7800
ggggcaggac agcaaggggg aggattggga agacaatagc aggcatgctg gggatgcggt 7860
gggctctatg gcctgcaggg gcgcctgatg cggtattttc tccttacgca tctgtgcggt 7920
atttcacacc gcatacgtca aagcaaccat agtacgcgcc ctgtagcggc gcattaagcg 7980
cggcgggtgt ggtggttacg cgcagcgtga ccgctacact tgccagcgcc ttagcgcccg 8040
ctcctttcgc tttcttccct tcctttctcg ccacgttcgc cggctttccc cgtcaagctc 8100
taaatcgggg gctcccttta gggttccgat ttagtgcttt acggcacctc gaccccaaaa 8160
aacttgattt gggtgatggt tcacgtagtg ggccatcgcc ctgatagacg gtttttcgcc 8220
ctttgacgtt ggagtccacg ttctttaata gtggactctt gttccaaact ggaacaacac 8280
tcaactctat ctcgggctat tcttttgatt tataagggat tttgccgatt tcggtctatt 8340
ggttaaaaaa tgagctgatt taacaaaaat ttaacgcgaa ttttaacaaa atattaacgt 8400
ttacaatttt atggtgcact ctcagtacaa tctgctctga tgccgcatag ttaagccagc 8460
cccgacaccc gccaacaccc gctgacgcgc cctgacgggc ttgtctgctc ccggcatccg 8520
cttacagaca agctgtgacc gtctccggga gctgcatgtg tcagaggttt tcaccgtcat 8580
caccgaaacg cgcgagacga aagggcctcg tgatacgcct atttttatag gttaatgtca 8640
tgataataat ggtttcttag acgtcaggtg gcacttttcg gggaaatgtg cgcggaaccc 8700
ctatttgttt atttttctaa atacattcaa atatgtatcc gctcatgaga caataaccct 8760
gataaatgct tcaataatat tgaaaaagga agagtatgag tattcaacat ttccgtgtcg 8820
cccttattcc cttttttgcg gcattttgcc ttcctgtttt tgctcaccca gaaacgctgg 8880
tgaaagtaaa agatgctgaa gatcagttgg gtgcacgagt gggttacatc gaactggatc 8940
tcaacagcgg taagatcctt gagagttttc gccccgaaga acgttttcca atgatgagca 9000
cttttaaagt tctgctatgt ggcgcggtat tatcccgtat tgacgccggg caagagcaac 9060
tcggtcgccg catacactat tctcagaatg acttggttga gtactcacca gtcacagaaa 9120
agcatcttac ggatggcatg acagtaagag aattatgcag tgctgccata accatgagtg 9180
ataacactgc ggccaactta cttctgacaa cgatcggagg accgaaggag ctaaccgctt 9240
ttttgcacaa catgggggat catgtaactc gccttgatcg ttgggaaccg gagctgaatg 9300
aagccatacc aaacgacgag cgtgacacca cgatgcctgt agcaatggca acaacgttgc 9360
gcaaactatt aactggcgaa ctacttactc tagcttcccg gcaacaatta atagactgga 9420
tggaggcgga taaagttgca ggaccacttc tgcgctcggc ccttccggct ggctggttta 9480
ttgctgataa atctggagcc ggtgagcgtg gaagccgcgg tatcattgca gcactggggc 9540
cagatggtaa gccctcccgt atcgtagtta tctacacgac ggggagtcag gcaactatgg 9600
atgaacgaaa tagacagatc gctgagatag gtgcctcact gattaagcat tggtaactgt 9660
cagaccaagt ttactcatat atactttaga ttgatttaaa acttcatttt taatttaaaa 9720
ggatctaggt gaagatcctt tttgataatc tcatgaccaa aatcccttaa cgtgagtttt 9780
cgttccactg agcgtcagac cccgtagaaa agatcaaagg atcttcttga gatccttttt 9840
ttctgcgcgt aatctgctgc ttgcaaacaa aaaaaccacc gctaccagcg gtggtttgtt 9900
tgccggatca agagctacca actctttttc cgaaggtaac tggcttcagc agagcgcaga 9960
taccaaatac tgttcttcta gtgtagccgt agttaggcca ccacttcaag aactctgtag 10020
caccgcctac atacctcgct ctgctaatcc tgttaccagt ggctgctgcc agtggcgata 10080
agtcgtgtct taccgggttg gactcaagac gatagttacc ggataaggcg cagcggtcgg 10140
gctgaacggg gggttcgtgc acacagccca gcttggagcg aacgacctac accgaactga 10200
gatacctaca gcgtgagcta tgagaaagcg ccacgcttcc cgaagggaga aaggcggaca 10260
ggtatccggt aagcggcagg gtcggaacag gagagcgcac gagggagctt ccagggggaa 10320
acgcctggta tctttatagt cctgtcgggt ttcgccacct ctgacttgag cgtcgatttt 10380
tgtgatgctc gtcagggggg cggagcctat ggaaaaacgc cagcaacgcg gcctttttac 10440
ggttcctggc cttttgctgg ccttttgctc acatgt 10476
<210> 3
<211> 3120
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 3
gacgaaaggg cctcgtgata cgcctatttt tataggttaa tgtcatgata ataatggttt 60
cttagacgtc aggtggcact tttcggggaa atgtgcgcgg aacccctatt tgtttatttt 120
tctaaataca ttcaaatatg tatccgctca tgagacaata accctgataa atgcttcaat 180
aatattgaaa aaggaagagt atgagtattc aacatttccg tgtcgccctt attccctttt 240
ttgcggcatt ttgccttcct gtttttgctc acccagaaac gctggtgaaa gtaaaagatg 300
ctgaagatca gttgggtgca cgagtgggtt acatcgaact ggatctcaac agcggtaaga 360
tccttgagag ttttcgcccc gaagaacgtt ttccaatgat gagcactttt aaagttctgc 420
tatgtggcgc ggtattatcc cgtattgacg ccgggcaaga gcaactcggt cgccgcatac 480
actattctca gaatgacttg gttgagtact caccagtcac agaaaagcat cttacggatg 540
gcatgacagt aagagaatta tgcagtgctg ccataaccat gagtgataac actgcggcca 600
acttacttct gacaacgatc ggaggaccga aggagctaac cgcttttttg cacaacatgg 660
gggatcatgt aactcgcctt gatcgttggg aaccggagct gaatgaagcc ataccaaacg 720
acgagcgtga caccacgatg cctgtagcaa tggcaacaac gttgcgcaaa ctattaactg 780
gcgaactact tactctagct tcccggcaac aattaataga ctggatggag gcggataaag 840
ttgcaggacc acttctgcgc tcggcccttc cggctggctg gtttattgct gataaatctg 900
gagccggtga gcgtgggtct cgcggtatca ttgcagcact ggggccagat ggtaagccct 960
cccgtatcgt agttatctac acgacgggga gtcaggcaac tatggatgaa cgaaatagac 1020
agatcgctga gataggtgcc tcactgatta agcattggta actgtcagac caagtttact 1080
catatatact ttagattgat ttaaaacttc atttttaatt taaaaggatc taggtgaaga 1140
tcctttttga taatctcatg accaaaatcc cttaacgtga gttttcgttc cactgagcgt 1200
cagaccccgt agaaaagatc aaaggatctt cttgagatcc tttttttctg cgcgtaatct 1260
gctgcttgca aacaaaaaaa ccaccgctac cagcggtggt ttgtttgccg gatcaagagc 1320
taccaactct ttttccgaag gtaactggct tcagcagagc gcagatacca aatactgttc 1380
ttctagtgta gccgtagtta ggccaccact tcaagaactc tgtagcaccg cctacatacc 1440
tcgctctgct aatcctgtta ccagtggctg ctgccagtgg cgataagtcg tgtcttaccg 1500
ggttggactc aagacgatag ttaccggata aggcgcagcg gtcgggctga acggggggtt 1560
cgtgcacaca gcccagcttg gagcgaacga cctacaccga actgagatac ctacagcgtg 1620
agctatgaga aagcgccacg cttcccgaag ggagaaaggc ggacaggtat ccggtaagcg 1680
gcagggtcgg aacaggagag cgcacgaggg agcttccagg gggaaacgcc tggtatcttt 1740
atagtcctgt cgggtttcgc cacctctgac ttgagcgtcg atttttgtga tgctcgtcag 1800
gggggcggag cctatggaaa aacgccagca acgcggcctt tttacggttc ctggcctttt 1860
gctggccttt tgctcacatg ttctttcctg cgttatcccc tgattctgtg gataaccgta 1920
ttaccgcctt tgagtgagct gataccgctc gccgcagccg aacgaccgag cgcagcgagt 1980
cagtgagcga ggaagcggaa gagcgcccaa tacgcaaacc gcctctcccc gcgcgttggc 2040
cgattcatta atgcagctgg cacgacaggt ttcccgactg gaaagcgggc agtgagcgca 2100
acgcaattaa tgtgagttag ctcactcatt aggcacccca ggctttacac tttatgcttc 2160
cggctcgtat gttgtgtgga attgtgagcg gataacaatt tcacacagga aacagctatg 2220
accatgatta cgccaagctt gcatgcaggc ctctgcagtc gacgggcccg ggatccgatg 2280
ataaacatgt gagggcctat ttcccatgat tccttcatat ttgcatatac gatacaaggc 2340
tgttagagag ataattggaa ttaatttgac tgtaaacaca aagatattag tacaaaatac 2400
gtgacgtaga aagtaataat ttcttgggta gtttgcagtt ttaaaattat gttttaaaat 2460
ggactatcat atgcttaccg taacttgaaa gtatttcgat ttcttggctt tatatatctt 2520
gtggaaagga cgaaacaccg ggtcttcgag aagacctgtt ttagagctag aaatagcaag 2580
ttaaaataag gctagtccgt tatcaacttg aaaaagtggc accgagtcgg tgcttttttc 2640
tagcgcgtgc gccaattctg cagacaaatg gctctagagg tacccataga tctagatgca 2700
ttcgcgaggt accgagctcg aattcactgg ccgtcgtttt acaacgtcgt gactgggaaa 2760
accctggcgt tacccaactt aatcgccttg cagcacatcc ccctttcgcc agctggcgta 2820
atagcgaaga ggcccgcacc gatcgccctt cccaacagtt gcgcagcctg aatggcgaat 2880
ggcgcctgat gcggtatttt ctccttacgc atctgtgcgg tatttcacac cgcatatggt 2940
gcactctcag tacaatctgc tctgatgccg catagttaag ccagccccga cacccgccaa 3000
cacccgctga cgcgccctga cgggcttgtc tgctcccggc atccgcttac agacaagctg 3060
tgaccgtctc cgggagctgc atgtgtcaga ggttttcacc gtcatcaccg aaacgcgcga 3120
<210> 4
<211> 175
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 4
tgtggaaagg acgaaacacc gggtcttcga gaagacctgt tttagagcta gaaatagcaa 60
gttaaaataa ggctagtccg ttatcaactt gaaaaagtgg caccgagtcg gtgctttttt 120
ctagcgcgtg cgccaattct gcagacaaat ggctctagag gtacccgtta cataa 175
<210> 5
<211> 554
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 5
tctgcagaca aatggctcta gaggtacccg ttacataact tacggtaaat ggcccgcctg 60
gctgaccgcc caacgacccc cgcccattga cgtcaatagt aacgccaata gggactttcc 120
attgacgtca atgggtggag tatttacggt aaactgccca cttggcagta catcaagtgt 180
atcatatgcc aagtacgccc cctattgacg tcaatgacgg taaatggccc gcctggcatt 240
gtgcccagta catgacctta tgggactttc ctacttggca gtacatctac gtattagtca 300
tcgctattac catgggggca gagcgcacat cgcccacagt ccccgagaag ttggggggag 360
gggtcggcaa ttgatccggt gcctagagaa ggtggcgcgg ggtaaactgg gaaagtgatg 420
tcgtgtactg gctccgcctt tttcccgagg gtgggggaga accgtatata agtgcagtag 480
tcgccgtgaa cgttcttttt cgcaacgggt ttgccgccag aacacaggtt ggaccggtgc 540
caccatggac tata 554
<210> 6
<211> 447
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 6
ccagaacaca ggttggaccg gtgccaccat ggactataag gaccacgacg gagactacaa 60
ggatcatgat attgattaca aagacgatga cgataagatg gcccccaaaa agaaacgaaa 120
ggtgggtggg tccccaaaga agaagcggaa ggtcggtatc cacggagtcc cagcagccga 180
caagaagtac agcatcggcc tggacatcgg caccaactct gtgggctggg ccgtgatcac 240
cgacgagtac aaggtgccca gcaagaaatt caaggtgctg ggcaacaccg accggcacag 300
catcaagaag aacctgatcg gagccctgct gttcgacagc ggcgaaacag ccgaggccac 360
ccggctgaag agaaccgcca gaagaagata caccagacgg aagaaccgga tctgctatct 420
gcaagagatc ttcagcaacg agatggc 447
<210> 7
<211> 2727
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 7
cggcggccac gaaaaaggcc ggccaggcaa aaaagaaaaa gggcggctcc aagcggcctg 60
ccgcgacgaa gaaagcggga caggccaaga aaaagaaagg atccggcgca acaaacttct 120
ctctgctgaa acaagccgga gatgtcgaag agaatcctgg accggtgagc aagggcgagg 180
agctgttcac cggggtggtg cccatcctgg tcgagctgga cggcgacgta aacggccaca 240
agttcagcgt gtccggcgag ggcgagggcg atgccaccta cggcaagctg accctgaagt 300
tcatctgcac caccggcaag ctgcccgtgc cctggcccac cctcgtgacc accctgacct 360
acggcgtgca gtgcttcagc cgctaccccg accacatgaa gcagcacgac ttcttcaagt 420
ccgccatgcc cgaaggctac gtccaggagc gcaccatctt cttcaaggac gacggcaact 480
acaagacccg cgccgaggtg aagttcgagg gcgacaccct ggtgaaccgc atcgagctga 540
agggcatcga cttcaaggag gacggcaaca tcctggggca caagctggag tacaactaca 600
acagccacaa cgtctatatc atggccgaca agcagaagaa cggcatcaag gtgaacttca 660
agatccgcca caacatcgag gacggcagcg tgcagctcgc cgaccactac cagcagaaca 720
cccccatcgg cgacggcccc gtgctgctgc ccgacaacca ctacctgagc acccagtccg 780
ccctgagcaa agaccccaac gagaagcgcg atcacatggt cctgctggag ttcgtgaccg 840
ccgccgggat cactctcggc atggacgagc tgtacaaggg ctccggcgag ggcaggggaa 900
gtcttctaac atgcggggac gtggaggaaa atcccggccc aaccgagtac aagcccacgg 960
tgcgcctcgc cacccgcgac gacgtcccca gggccgtacg caccctcgcc gccgcgttcg 1020
ccgactaccc cgccacgcgc cacaccgtcg atccggaccg ccacatcgag cgggtcaccg 1080
agctgcaaga actcttcctc acgcgcgtcg ggctcgacat cggcaaggtg tgggtcgcgg 1140
acgacggcgc cgcggtggcg gtctggacca cgccggagag cgtcgaagcg ggggcggtgt 1200
tcgccgagat cggcccgcgc atggccgagt tgagcggttc ccggctggcc gcgcagcaac 1260
agatggaagg cctcctggcg ccgcaccggc ccaaggagcc cgcgtggttc ctggccaccg 1320
tcggagtctc gcccgaccac cagggcaagg gtctgggcag cgccgtcgtg ctccccggag 1380
tggaggcggc cgagcgcgcc ggggtgcccg ccttcctgga gacctccgcg ccccgcaacc 1440
tccccttcta cgagcggctc ggcttcaccg tcaccgccga cgtcgaggtg cccgaaggac 1500
cgcgcacctg gtgcatgacc cgcaagcccg gtgcctgaac gcgttaagtc gacaatcaac 1560
ctctggatta caaaatttgt gaaagattga ctggtattct taactatgtt gctcctttta 1620
cgctatgtgg atacgctgct ttaatgcctt tgtatcatgc tattgcttcc cgtatggctt 1680
tcattttctc ctccttgtat aaatcctggt tgctgtctct ttatgaggag ttgtggcccg 1740
ttgtcaggca acgtggcgtg gtgtgcactg tgtttgctga cgcaaccccc actggttggg 1800
gcattgccac cacctgtcag ctcctttccg ggactttcgc tttccccctc cctattgcca 1860
cggcggaact catcgccgcc tgccttgccc gctgctggac aggggctcgg ctgttgggca 1920
ctgacaattc cgtggtgttg tcggggaaat catcgtcctt tccttggctg ctcgcctgtg 1980
ttgccacctg gattctgcgc gggacgtcct tctgctacgt cccttcggcc ctcaatccag 2040
cggaccttcc ttcccgcggc ctgctgccgg ctctgcggcc tcttccgcgt cttcgccttc 2100
gccctcagac gagtcggatc tccctttggg ccgcctcccc gcgtcgactt taagaccaat 2160
gacttacaag gcagctgtag atcttagcca ctttttaaaa gaaaaggggg gactggaagg 2220
gctaattcac tcccaacgaa gacaagatct gctttttgct tgtactgggt ctctctggtt 2280
agaccagatc tgagcctggg agctctctgg ctaactaggg aacccactgc ttaagcctca 2340
ataaagcttg ccttgagtgc ttcaagtagt gtgtgcccgt ctgttgtgtg actctggtaa 2400
ctagagatcc ctcagaccct tttagtcagt gtggaaaatc tctagcaggg cccgtttaaa 2460
cccgctgatc agcctcgact gtgccttcta gttgccagcc atctgttgtt tgcccctccc 2520
ccgtgccttc cttgaccctg gaaggtgcca ctcccactgt cctttcctaa taaaatgagg 2580
aaattgcatc gcattgtctg agtaggtgtc attctattct ggggggtggg gtggggcagg 2640
acagcaaggg ggaggattgg gaagacaata gcaggcatgc tggggatgcg gtgggctcta 2700
tggcctgcag gggcgcctga tgcggta 2727
<210> 8
<211> 410
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 8
gataaacatg tgagggccta tttcccatga ttccttcata tttgcatata cgatacaagg 60
ctgttagaga gataattgga attaatttga ctgtaaacac aaagatatta gtacaaaata 120
cgtgacgtag aaagtaataa tttcttgggt agtttgcagt tttaaaatta tgttttaaaa 180
tggactatca tatgcttacc gtaacttgaa agtatttcga tttcttggct ttatatatct 240
tgtggaaagg acgaaacacc gggtcttcga gaagacctgt tttagagcta gaaatagcaa 300
gttaaaataa ggctagtccg ttatcaactt gaaaaagtgg caccgagtcg gtgctttttt 360
ctagcgcgtg cgccaattct gcagacaaat ggctctagag gtacccatag 410
<210> 9
<211> 20
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 9
agttatggca gaactcagtg 20
<210> 10
<211> 23
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 10
ccccatccaa agtttttaaa gga 23
<210> 11
<211> 23
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 11
tgtggcagat gtcacagttt agg 23
<210> 12
<211> 25
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 12
caccgagtta tggcagaact cagtg 25
<210> 13
<211> 25
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 13
aaaccactga gttctgccat aactc 25
<210> 14
<211> 1999
<212> DNA
<213> 猪(Sus scrofa)
<400> 14
agaagcagag gaggagccac tgtgcacatt tttttttccc cttcacacac cataaaaatc 60
acagaggcaa ctaacactca cagcaaagct tcaggttggg aactgattct ctctgcgagg 120
cagctgatct gagcatgcgc acacagattc attcttctcc caatagcaca gcagccgcta 180
ggaaaattat tttgaaaaga cctgaatgca ttaagactaa agttaaagtg gaagtgagaa 240
caaaatatca aacagcagac tcgacagaga atgagcgtct tgaagcctaa gatttcaaag 300
tgatgctaat cagagcccta cctgaaagag actaaaaact ccatttcaag cttcggagca 360
tgtgatattt attcacaaca ggcattccaa tttcagcctc ataactttca gacagataaa 420
gacttggaga aaatcgctga ggctacctga cccaggagct taaatcaggt cagaggggat 480
ctcaacccac ctggcgcagg atgaactcaa cccatcacca tggaatgcat acttctctcc 540
acttctggaa ccgcagcacc tacggactgc acagcaatgc cagtgagccc cttggaaaag 600
gctactctga aggaggatgc tacgagcaac tttttgtctc tcctgaggtg tttgtgactc 660
tgggtgtcat aagcctgttg gagaacattc tggtgattgt ggccatagcc aagaacaaga 720
atctgcattc acccatgtac tttttcatct gtagcctggc tgtggctgat atgctggtga 780
gcgtttccaa tgggtcagaa accattgtca tcaccctatt aaacagcacg gacacggacg 840
cacagagttt cacagtgaat attgataatg tcattgactc agtgatctgt agctccttac 900
tcgcctcaat ttgcagcctg ctttcgattg cagtggacag gtattttact atcttttatg 960
ctctccagta ccataacatt atgacagtta agcgggttgg aatcatcatc agttgtatct 1020
gggcagtctg cacggtgtcg ggtgttttgt tcatcattta ctcagatagc agtgctgtta 1080
ttatctgcct cataaccgtg ttcttcacca tgctggctct catggcttct ctctatgtcc 1140
acatgttcct catggccaga ctccacatta agaggatcgc cgtcctccca ggcactggca 1200
ccatccgcca aggtgccaac atgaaggggg caattaccct gaccatcttg attggggtct 1260
ttgtggtctg ctgggccccc ttcttcctcc acttaatatt ctatatctcc tgcccccaga 1320
atccatactg tgtgtgcttc atgtctcact ttaatttgta tctcatcctg atcatgtgta 1380
attccatcat cgatcccctg atttatgcac tccggagcca agaactgagg aaaaccttca 1440
aagagatcat ctgttgctat cccctgggtg gcctctgtga tttgtctagc agatattaaa 1500
tggggacaga ggagacttat aaatgcaagc ataagagact ttctccttac acagtctgga 1560
caatatgctt caacaacagc attttcttgt aaggcatcag ttgagacatt ctattgtata 1620
aatttaagtt cgtgattctg ctcagtctct gtgtattttt aaggtcttgc taccttttgg 1680
ctgtaaaatg tttatctata ctacaggtta taggcacaat ggatttataa aaaagaaaaa 1740
agtccttatg aaaagttaat taatgtatct tgtcattcga aaggatttga cacattgctt 1800
gttttagtaa aatggaaatc acagtttcat taaatatatc ctaataaatg gttgctaata 1860
ttacactata caacgctgaa gtgtagaggt ttgattctag cattgagggg agaaatactg 1920
aaacaagtgt ttaatcatta aaaaataagc tgaaatttca actaatttaa taaaacatgc 1980
tcattctccc tgtgcagaa 1999
<210> 15
<211> 213
<212> PRT
<213> 猪(Sus scrofa)
<400> 15
Met Asn Ser Thr His His His Gly Met His Thr Ser His Trp Asn Arg
1 5 10 15
Ser Thr Tyr Gly His Ser Asn Ala Ser Gly Lys Gly Tyr Ser Gly Gly
20 25 30
Cys Tyr Val Ser Val Val Thr Gly Val Ser Asn Val Val Ala Ala Lys
35 40 45
Asn Lys Asn His Ser Met Tyr Cys Ser Ala Val Ala Asp Met Val Ser
50 55 60
Val Ser Asn Gly Ser Thr Val Thr Asn Ser Thr Asp Thr Asp Ala Ser
65 70 75 80
Thr Val Asn Asp Asn Val Asp Ser Val Cys Ser Ser Ala Ser Cys Ser
85 90 95
Ser Ala Val Asp Arg Tyr Thr Tyr Ala Tyr His Asn Met Thr Val Lys
100 105 110
Arg Val Gly Ser Cys Trp Ala Val Cys Thr Val Ser Gly Val Tyr Ser
115 120 125
Asp Ser Ser Ala Val Cys Thr Val Thr Met Ala Met Ala Ser Tyr Val
130 135 140
His Met Met Ala Arg His Lys Arg Ala Val Gly Thr Gly Thr Arg Gly
145 150 155 160
Ala Asn Met Lys Gly Ala Thr Thr Gly Val Val Val Cys Trp Ala His
165 170 175
Tyr Ser Cys Asn Tyr Cys Val Cys Met Ser His Asn Tyr Met Cys Asn
180 185 190
Ser Asp Tyr Ala Arg Ser Arg Lys Thr Lys Cys Cys Tyr Gly Gly Cys
195 200 205
Asp Ser Ser Arg Tyr
210
<210> 16
<211> 19
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 16
tccacttctg gaaccgcag 19
<210> 17
<211> 21
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 17
tccaacccgc ttaactgtca t 21
<210> 18
<211> 20
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 18
catcacccta ttaaacagca 20
<210> 19
<211> 20
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 19
cctattaaac agcacggaca 20
<210> 20
<211> 20
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 20
atgctggtga gcgtttccaa 20
<210> 21
<211> 20
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 21
ctacagatga aaaagtacat 20
<210> 22
<211> 100
<212> RNA
<213> 人工序列(Artificial Sequence)
<400> 22
caucacccua uuaaacagca guuuuagagc uagaaauagc aaguuaaaau aaggcuaguc 60
cguuaucaac uugaaaaagu ggcaccgagu cggugcuuuu 100
<210> 23
<211> 100
<212> RNA
<213> 人工序列(Artificial Sequence)
<400> 23
ccuauuaaac agcacggaca guuuuagagc uagaaauagc aaguuaaaau aaggcuaguc 60
cguuaucaac uugaaaaagu ggcaccgagu cggugcuuuu 100
<210> 24
<211> 100
<212> RNA
<213> 人工序列(Artificial Sequence)
<400> 24
augcugguga gcguuuccaa guuuuagagc uagaaauagc aaguuaaaau aaggcuaguc 60
cguuaucaac uugaaaaagu ggcaccgagu cggugcuuuu 100
<210> 25
<211> 100
<212> RNA
<213> 人工序列(Artificial Sequence)
<400> 25
cuacagauga aaaaguacau guuuuagagc uagaaauagc aaguuaaaau aaggcuaguc 60
cguuaucaac uugaaaaagu ggcaccgagu cggugcuuuu 100
<210> 26
<211> 25
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 26
caccgcatca ccctattaaa cagca 25
<210> 27
<211> 25
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 27
aaactgctgt ttaatagggt gatgc 25
<210> 28
<211> 25
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 28
caccgcctat taaacagcac ggaca 25
<210> 29
<211> 25
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 29
aaactgtccg tgctgtttaa taggc 25
<210> 30
<211> 25
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 30
caccgatgct ggtgagcgtt tccaa 25
<210> 31
<211> 25
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 31
aaacttggaa acgctcacca gcatc 25
<210> 32
<211> 25
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 32
caccgctaca gatgaaaaag tacat 25
<210> 33
<211> 25
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 33
aaacatgtac tttttcatct gtagc 25
Claims (4)
1.一种用于猪MC4R基因编辑的CRISPR/Cas9系统,其特征在于包含Cas9表达载体和针对猪MC4R基因的gRNA表达载体;所述的Cas9表达载体为质粒全序列如SEQ ID NO.2所示的pU6gRNA-eEF1a-mNLS-hSpCas9-EGFP-PURO载体;所述的针对猪MC4R基因的gRNA表达载体由SEQ ID NO.26和SEQ ID NO.27所示的单链DNA退火而成的双链插入载体骨架pKG-U6gRNA所得;该表达载体表达SEQ ID NO.22所示的gRNA,其靶点如SEQ ID NO.18所示;所述的的载体骨架pKG-U6gRNA的质粒全序列如SEQ ID NO.3所示;所述的gRNA表达载体和Cas9表达载体的摩尔比为3:1。
2.一种敲除猪MC4R基因的猪重组细胞,其特征在于由权利要求1所述的CRISPR/Cas9系统共转染猪原代成纤维细胞经验证后所得。
3.权利要求2所述的重组细胞在构建MC4R基因敲除的克隆猪中的应用。
4.权利要求1所述的CRISPR/Cas9系统在构建猪MC4R基因敲除的猪重组细胞中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011504254.9A CN112608941B (zh) | 2020-12-18 | 2020-12-18 | 用于构建mc4r基因突变的肥胖症猪核移植供体细胞的crispr系统及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011504254.9A CN112608941B (zh) | 2020-12-18 | 2020-12-18 | 用于构建mc4r基因突变的肥胖症猪核移植供体细胞的crispr系统及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112608941A CN112608941A (zh) | 2021-04-06 |
CN112608941B true CN112608941B (zh) | 2023-03-21 |
Family
ID=75240544
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011504254.9A Active CN112608941B (zh) | 2020-12-18 | 2020-12-18 | 用于构建mc4r基因突变的肥胖症猪核移植供体细胞的crispr系统及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112608941B (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106191064A (zh) * | 2016-07-22 | 2016-12-07 | 中国农业大学 | 一种制备mc4r基因敲除猪的方法 |
CN107119053A (zh) * | 2017-06-23 | 2017-09-01 | 东北农业大学 | 一种特异靶向猪MC4R基因的sgRNA导向序列及其应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3018200A1 (en) * | 2014-11-07 | 2016-05-11 | Fondazione Matilde Tettamanti e Menotti de Machi Onlus | Improved method for the generation of genetically modified cells |
-
2020
- 2020-12-18 CN CN202011504254.9A patent/CN112608941B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106191064A (zh) * | 2016-07-22 | 2016-12-07 | 中国农业大学 | 一种制备mc4r基因敲除猪的方法 |
CN107119053A (zh) * | 2017-06-23 | 2017-09-01 | 东北农业大学 | 一种特异靶向猪MC4R基因的sgRNA导向序列及其应用 |
Non-Patent Citations (3)
Title |
---|
A Non-integrating Lentiviral Approach Overcomes Cas9-Induced Immune Rejection to Establish an Immunocompetent Metastatic Renal Cancer Model;Hu等;《Mol Ther Methods Clin Dev》;20180630;第9卷;第204页图1 * |
analysis of an aggrecan knockout cell line.《Bone》.2014,第69卷 * |
Yang等.CRISPR/Cas9 mediated generation of stable chondrocyte cell lines with targeted gene knockouts * |
Also Published As
Publication number | Publication date |
---|---|
CN112608941A (zh) | 2021-04-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112779292B (zh) | 构建瘦肉率高、生长快且抗蓝耳病和系列腹泻病的优质猪核移植供体细胞的方法及其应用 | |
CN112522261B (zh) | 用于制备lmna基因突变的扩张型心肌病克隆猪核供体细胞的crispr系统及其应用 | |
CN112779291B (zh) | 构建瘦肉率高、生长快、繁殖力高且抗系列流行病的优质猪核移植供体细胞的方法及其应用 | |
CN112522264B (zh) | 一种导致先天性耳聋的CRISPR/Cas9系统及其在制备模型猪核供体细胞中的应用 | |
CN112522260B (zh) | Crispr系统及其在制备ttn基因突变的扩张型心肌病克隆猪核供体细胞中的应用 | |
CN114958762B (zh) | 一种构建神经组织特异过表达人源snca的帕金森病模型猪的方法及应用 | |
CN112877362A (zh) | 构建高繁殖力、抗蓝耳病和系列腹泻病的优质猪核移植供体细胞的基因编辑系统及其应用 | |
CN113046388B (zh) | 用于构建双基因联合敲除的动脉粥样硬化猪核移植供体细胞的crispr系统及其应用 | |
CN112680444B (zh) | 用于oca2基因突变的crispr系统及其在构建白化病克隆猪核供体细胞中的应用 | |
CN112522313B (zh) | 用于构建TPH2基因突变的抑郁症克隆猪核供体细胞的CRISPR/Cas9系统 | |
CN112522309B (zh) | 重症免疫缺陷猪源重组细胞及其制备方法和试剂盒 | |
CN112877363A (zh) | 一种构建瘦肉率高、生长快且繁殖力高的优质猪核移植供体细胞的基因编辑系统及其应用 | |
CN112608941B (zh) | 用于构建mc4r基因突变的肥胖症猪核移植供体细胞的crispr系统及其应用 | |
CN112522311B (zh) | 用于adcy3基因编辑的crispr系统及其在构建肥胖症猪核移植供体细胞中应用 | |
CN112813101B (zh) | 一种构建瘦肉率高、生长快的优质猪核移植供体细胞的基因编辑系统及其应用 | |
CN113584078B (zh) | 用于双靶标基因编辑的crispr系统及其在构建抑郁症猪核移植供体细胞中的应用 | |
CN112795566B (zh) | 用于构建骨质疏松症克隆猪核供体细胞系的opg基因编辑系统及其应用 | |
CN112575033B (zh) | Crispr系统及其在构建scn1a基因突变的癫痫性脑病克隆猪核供体细胞中的应用 | |
CN112899306B (zh) | Crispr系统及其在构建gabrg2基因突变的克隆猪核供体细胞中的应用 | |
CN112522258B (zh) | Il2rg基因和ada基因联合敲除的重组细胞及其在制备免疫缺陷猪模型中的应用 | |
CN112522202B (zh) | 制备addi四个基因联合敲除的重症免疫缺陷猪源重组细胞的方法及其专用试剂盒 | |
CN112680453B (zh) | Crispr系统及其在构建stxbp1突变的癫痫性脑病克隆猪核供体细胞中的应用 | |
CN112522256B (zh) | CRISPR/Cas9系统及其在构建抗肌萎缩蛋白基因缺陷的猪源重组细胞中的应用 | |
CN112522257B (zh) | 用于制备rrip四个基因联合敲除的重症免疫缺陷猪源重组细胞的系统 | |
CN112522255B (zh) | CRISPR/Cas9系统及其在构建胰岛素受体底物基因缺陷的猪源重组细胞中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |